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The following extended abstracts were presented at a Research Initia- 
tives in Vascular Disease Symposium, How to Build a Blood Vessel, 
sponsored by The Lifeline Foundation; the International Society for 
Cardiovascular Surgery, North American Chapter; and The Society for 
Vascular Surgery on Feb. 27-28, 1997, in Bethesda, Md. 
VASCULOGENESIS 
EARLY DEVELOPMENT OF 
ENDOTHELIAL TUBES 
The embryonic irculatory system forms from the intraembryonic 
and extraembryonic mesoderm. We have chosen to study the 
formation of intraembryonic vessels (stage 7-10) because their 
morphogenesis is both well characterized and free of hematopoie- 
sis. The first blood vessels to form in the embryo arise from a 
population of mesodermal cells referred to as angioblasts. How 
this population of cells is transformed into embryonic vascular 
endothelial tubes is the focus of our research. 
The best marker for endothelial cells is the mouse monoclonal 
antibody QH-1. The QH-1 antibody recognizes a carbohydrate 
epitope present on the surface of quail endothelial cells from early 
in development until adulthood, and readily distinguishes the 
primitive vasculature from surrounding embryonic cells. 1 Al- 
though QH-1 is useful in the identification of  endothelial cells, it 
has not been established as a marker ofangioblasts. Efforts on our 
part to study the earliest events ofvasculogenesis have led to new 
data regarding the identification of angioblasts. Our observations 
establish a new marker that distinguishes angioblasts from QH-1- 
positive primordial endothelial cells (unpublished ata). The 
marker is the transcription factor TAL1/SCL (hereafter referred 
to  as TALl),  a member of the basic-helix-loop-helix family of  
transcription factors. 2 
Double immunofluorescence confocal microscopy using anti- 
bodies to TALl and the QH-1 antigen show that TALl expres- 
sion precedes that of QH-1 antigen. This difference in expression 
is most evident in confocal analysis of the splanchnic mesoderm at 
stage 7. We detect within the mesoderm a subpopulation of cells 
that are positive for TALl and negative for QH-1. The TALl- 
positive cells are initially observed as isolated cells separated from 
other TALl-positive cells by intervening mesoderm. This sub- 
population is distributed in an apparently random pattern. Analy- 
sis of  their cellular distribution does not predict the eventual 
vascular pattern. 
The QH-1 epitope is first detected when TALl-positive cells 
aggregate. In fact, there is a direct correlation between the num- 
ber of TALl-positive cells (angioblasts) in an aggregate and the 
level of  QH-1 expression. Aggregates containing one to three 
TALl-positive cells are weakly QH-1 immunoreactive, whereas 
vessel primordia composed of  6-9 cells are intensely immunola- 
beled. We refer to the cells that comprise these aggregates as 
primordial endothelial cells to distinguish them from both angio- 
blasts and endothelial cells enclosing a lumen. Thus according to 
our model ofvasculogenesis, QH-1 expression is associated with 
the transition from angioblast to primordial endothelial cells. The 
QH-1 epitope is first expressed when cells engage in assembly of 
primordial vascular aggregates. In short, we propose that isolated, 
TALl-positive/QH-1-negative cells are angioblasts, whereas clus- 
In order to ensure the widest dissemination possible, these ab- 
stracts also will appear in the July issue of the Journal of Vascular 
and Interventional Radiology (published by Lippincott-Raven). 
tered, TALl-posit ive/QH 1-positive cells are primordial endo- 
theliai cells or their descendants (unpublished data). 
Having established that primordial endothelial cells, as de- 
fined above, are confined to small aggregates that express the 
QH-1 epitope, what are the next morphologic events? In vivo 
studies examining vasculogenesis in quail indicate that primordial 
endothelial cells tend to elongate and form short chainlike assem- 
blies of cells oriented in a linear fashionfi Concurrent with this 
activity, the endothelial cells that comprise these vascular segments 
become polarized and form lumens; however, the molecular 
mechanisms underlying each of these morphogenic events are 
poorly understood. 
The next morphologic event is the assembly of isolated vascu- 
lar segments into a vascular network. This reqtfires that endothelial 
cells engage in protrusive activity and cell-shape change such that 
filopodia re projected outward from the cell body. Extensive protru- 
sive activity by endothelial cells results in the establishment of stable 
contacts between earby cells and the beginning of a primitive vascu- 
iar network. Thus begins the formation of a highly ordered pattern of 
hexagonal polygons composed of endothelial cells. In avians, this 
process occurs in a plane ofextracellular matrix between the overlying 
splanchnic mesoderm and the underlying endoderm. 
Protrusive activity on the part of endothelial cells requires 
extracellular matrix adhesions that can be mediated by a number 
of molecular mechanisms, including members of the integrin 
family of cell surface receptors. To determine which integrins are 
involved in the morphogenesis of embryonic blood vessels and 
vascular networks, we devised an ex vivo microinjection system, 
whereby integrin inhibitors, and other experimental reagents, 
could be introduced into the primary vascular fields. Our initial 
work in quail showed that the mouse monoclonai antibody CSAT, 
which inhibits all members of the J31-integrin family, will cause 
vascular developmental anomalies, including disruption of primary 
vascular networks. 4 This experimental intervention was somewhat 
nonspecific, however, because there are numerous members of the 
~31-integrin family; consequently, it was not possible to assign 
function to a specific [31-integrin(s). 
Work by others, however, offered the opportunity to test the 
function of a single integfin in the assembly of vessels,  This group 
had shown that ~v133 plays a fundamental role in angiogenesis 
(vessel formation from preexisting vessels). Accordingly, we mi- 
croinjected the mouse monoclonal antibody, LM609, into the 
vasculogenic region of four somite quail embryos. This c~v133 
antagonist induced distinct vascular abnormalities. Primordial en- 
dothelial cell aggregates failed to form a normal polygonal net- 
work. Instead, small islands of cells were observed in which no 
connections (protrusions) to nearby endothelial assemblies were 
observed. Further, no fine vascular cellular processes were ob- 
served, and large vessels uch as the dorsal aortae were abnormal. 
These effects are the result of  a local, acute, dominant negative 
inhibition of c¢v133 integrin function, and are direct evidence that 
c~v133 is involved in formation of a primary vascular network and 
successful aortic morphogenesis. 6 
We also used the quail embryo microinjecfion system to assess 
the in vivo function of the endothelial cytoldne, vascular endothe 
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lial growth factor (VEGF). Considerable work has shown that 
VEGF is a potent, specific, endothelial mitogen and that abroga- 
tion of the VEGF gene in mice results in severe vascular deformi- 
ties. 7 Recombinant human VEGF16 s is active in quails, and injec- 
tion into early vasculogenic stage embryos caused profound 
vascular malformations. Two vascular anomalies were noted: (1) 
elevated levels of fine cellular protrusions, including processes 
extending into normally avascular regions; and (2) an unregu- 
lated, progressive fusion of small-caliber vessels into larger-caliber 
vessels, such that by 6 hours after injection, there were essentially 
only two "vessels" present in the embryo---that is,a large vascular 
sinus on each side of the embryonic axis. 
Normal morphogenesis of the dorsal aortae entails tightly 
regulated fusion of many small-caliber vessels to form a larger 
vessel (unpublished data). Once formed, the paired aortae move 
to the midline, where they join to form a single centrally-located 
vessel ventral to the notochord the descending aorta. Until this 
point, the endothelial ceils that form the vessels of the embryo are not 
associated with accessory cells. That is, the vascular tubes are com- 
posed of a single layer of endothelium. As the two aortic rudiments 
are drawn to the midline, they fuse in a cranial-to-caudal f shion; such 
that in a single embryo there are cranial positions with a "one-tube" 
descending aorta, a region of fusion, and a caudal region where two 
separate tubes (dorsal aortae) are found. 
At this stage of aortic morphogenesis, a population of meso- 
dermal cells becomes affiliated with the ventral aspect of the tubes. 
This is the first evidence of presumptive smooth muscle cells. 9 
Subsequently, this ventral cell layer increases in thickness, and 
similar cells begin to appear at the dorsal aspect of the aorta. Using 
four cytoskeletal markers and two ECM markers, we have shown 
that a progressive wave of smooth muscle differentiation ccurs in 
a ventral to dorsal direction in the descending aorta. The first 
marker detected was smooth muscle ~-actin, followed by a novel 
marker, the 1E12 antigen, then calponin, and finally smooth 
muscle myosin heavy chain. 9,~° Moreover, cell proliferation data 
show that while this progressive wave of differentiation is taking 
place the embryonic smooth muscle cells are actively engaged in 
proliferation. TM Our work also shows that the 1E12 antigen is a 
variant of the smooth muscle c~-actinins; and that this antigen is, to 
the best of our knowledge, the earliest known unequivocal marker 
for cells specified to the lineage of smooth muscle. 9 
In summary, our data establish a novel marker for angioblasts, 
demonstrate a role for integrin-mediated cell adhesion during 
formation of primary vascular networks, and establish that vessel 
caliber and the ability of primordial endothelial cells to obey 
morphologic boundaries are directly influenced by VEGF. Fur- 
ther, we describe a novel marker for primordial smooth muscle 
cells and show that the assembly of the aortic wall entails a 
progressive wave of differentiation from ventral to dorsal. This 
work represents a comprehensive program of investigation to 
understand blood vessel formation de novo. 
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ORIG IN  AND RECRUITMENT OF SMOOTH 
MUSCLE CELLS DURING 
VESSEL DEVELOPMENT 
Development of the tunica media begins with assembly of primi- 
tive endothelial cells into an extensive network of capillary-like 
vessels that quickly reaches all parts of the growing embryo. 1The 
onset of cardiac ontractile activity starts the circulation of blood, 
and shortly thereafter endothelial cells begin to recruit smooth 
muscle cells (SMCs) from locally available progenitors to form a 
supporting tunica media. As a consequence of the widespread 
distribution of the primitive vascular network, SMCs are necessar- 
ily recruited from diverse primary origins. Although these general 
aspects of vascular development have been known for many years, 
we still do not know the identity of endothelial-derived signals 
that recruit mesenchymal cells to a smooth muscle fate, the signal 
transduction and transcription pathways that control vessel wall 
formation in the embryo, nor the role that diversity of SMC 
lineage background plays in functional heterogeneity of adult 
SMCs. As discussed below, recent studies have begun to provide 
new insights into these and other questions about the molecular 
controls of vessel wall formation in development. 
Mu l t ip le  o r ig ins  fo r  vascu lar  smooth  musc le  
cel ls  in  the  embryo  
Once the basic pattern of capillary-like vessels has been estab- 
lished in the embryo, the next step in wail formation is the 
assembly ofa tunica media. The central questions are (1) where do 
medial SMCs come from in the embryo; and (2) what signals do 
endothelial cells produce to recruit mesenchymal cells to a SMC 
fate? Lineage mapping studies using chick-quail chimeric embryos 
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have established that the aortic tunica media in the avian embryo is 
composed of SMCs that arise from two different primary lineages 
in development. 2 One lineage descends from progenitors in the 
cardiac neural crest and is therefore neural ectoderm in origin (Ect 
SMCs). The other lineage originates from lateral mesoderm-de- 
rived mesenchyme that surrounds the developing outflow elastic 
arteries (Mes SMCs). The two SMC types are not equally distrib- 
uted within the tunica media but exhibit sharp boundaries and 
transition zones, aEct SMCs are the predominant orexclusive type 
of SMC in the proximal segments of the major heart outflow 
vessels (aorta, common carotid, pulmonary and brachlocephalic 
arteries, ductus arteriosus), whereas Mes SMCs are the only SMC 
type in the distal segments of these vessels. 2,4 
More recent studies using retroviral markers and fluorescent 
lineage tracer dyes have provided evidence for yet a third indepen- 
dent origin for vascular SMCs in the embryo. Progenitors for 
coronary artery SMCs originate from extracardiac coelomic me- 
sothelium and reside within the proepicardial organ (PEO), a 
transient structure that projects from the ventral body wall, makes 
contact with the looped heart ube, and gives rise to the epicardial 
cells that cover the external surface of the heart, s Using expression 
of calponin as a SMC marker, we have examined saggital sections 
through the heart and PEO during the period of coronary vascu- 
logenesis in the avian embryo. Calponin is not expressed in the 
PEO itself at embryonic day 2.5 (ED 2.5), nor in migratory 
epicardial epithelium during invasion and coverage of the myocar- 
dial surface. Calponin immunoreactivity is first detected in mesen- 
chymal cells within the subepicardial space in association with 
newly formed epithelial channels at ED 5.5. Calponin-positive 
cells adjacent o the endothelinm coexpress (x-smooth muscle 
actin and desmin. These results uggest hat a subpopulation of
PEO-derived epicardial ceils undergo an epithelial to mesenchy- 
mal transformation, i vade the subepiccardial matrix, respond to 
signals produced by the endothelium, and acquire a SMC pheno- 
type. To examine this possibility in greater detail, we developed 
methods to study calponin expression in single explanted quail 
embryo PEOs grown in vitro. Similar to findings in vivo, ex- 
planted PEO cultures grew out as an epithelial sheet hat did not 
initially exhibit calponin immunoreactivity. By approximately 3 
days after explanting, the calponin gene becomes trongly ex- 
pressed in a subpopulation fcells that acquire a migratory, fibro- 
blastic phenotype at the periphery of the outgrowth. Calponin- 
positive cells coexpress (x-smooth muscle actin and desmin, similar 
to nascent coronary SMCs in vivo. Quantitative RT-PCR analysis 
of single PEO explant cultures is currently being used to examine 
the effects of factors derived from the endothelium, myocardium, 
and subepicardial matrix on expression ofcalponin and other SMC 
markers in proepicardial cells in vitro. 
Further evidence for SMC origins from locally available mes- 
enchymal progenitor cells comes from the work ofHungerford et 
al. 6 These authors provided evidence that recruitment of aortic 
SMC progenitors occurs in a ventral to dorsal grandient as well as 
in a radial direction emanating from the endothelium. Thus SMCs 
are recruited from multiple origins in the developing embryo 
under the direction of endothelial cell-derived signals. 
Or ig ins  o f  smooth  musc le  cel ls  in  mammal ian  
embryos  
Most of what we lmow about unica media formation comes 
from experimental studies on the avian embryo. However, a varb 
ety of evidence now suggests that the pattern of neural crest cell 
contribution to the developing outflow tract and aortic arch arter- 
ies is strictly conserved between avian and mammalian species. 4 
Moreover, a number of congenital human diseases comprising 
heart and outflow tract malformations are attributed to failure of 
proper contribution by the cardiac neural crest derivatives to the 
developing aortic arch complex. 3 In addition, targeted gene dele- 
tion studies provide molecular evidence of conserved signaling 
pathways operating throughout vertebrate development to con- 
trol formation of the vascular system. 
Recru i tment  and  wa l l  fo rmat ion :  mul t ip le  s teps  
in t tmica  med ia  fo rmat ion  
What are the signals produced by endothelial cells that recruit 
SMC progenitors to form a tunica media? Speculation has cen- 
tered on factors with known chemoattractant effects on vascular 
SMCs, such as PDGF-BB, basic FGF, endothelin-1, and HB- 
EGF. Recent gene deletion studies from Betsholtz and coworkers 
provide evidence to support such a role for PDGF-BB, at least in 
microvessels. 7 More surprising is the role proposed for a recently 
discovered ligand for the endothelial cell-specific Tie2 receptor 
called angiopoietin-1, s Tie2-deficient mouse embryos die by ED 
10.5 with malformations of the capillaryqike vascular network, 
including dilated vessels, hemorrhaging, and defects in secondary 
network remodeling. 9 Angiopoietin-l-deficient mice have a very 
similar pattern of vascular network defects and are also embryonic 
lethal. A strildng feature of both Tie2 and angiopoietin-l-null 
mice is a deficiency in recruitment of medial SMCs and pericytes. 
Because angiopoietin-1 is produced by mesenchymal cells sur- 
rounding developing vessels, these results suggest a interactive 
feedback loop between endothelial cells and SMC progenitor 
cells. It will be interesting to determine (1) whether angiopoi- 
etin-1 directly regulates the production of SMC chemoattractants 
and differentiation-inducing factors uch as PDGF~BB and TGF-[3 
by endothelial cells; and (2) what factors regulate angiopoietin-1 
production by mesenchymal cells. 
Once SMC progenitors have become assembled around a 
developing endothelial channel the next step in wall formation 
begins. SMCs must produce a highly organized extracellular ma 
trix and a multilayered tunica media. This process involves two 
prolonged steps that extensively overlap in time. The first is prolif- 
eration and production of a provisional matrix to organize the 
newly formed SMCs. The second is a gradual acquisition (matura~ 
tion) of contractile proteins and cytoskeletal elements o produce a
contractile vessel wail that can respond to vasoactive and neural 
stimuli by excitation-contraction c upling. This occurs together 
with synthesis and assembly of a mature collagen and elastin-tich 
extracellular matrix capable of supporting the increasing intramu- 
ral tension produced by increasing blood pressures. Very little is 
currently lmown about the signals that control these steps in 
tunica media formation. 
Re la t ion  between SMC l ineage  d ivers i ty  in  the  
embryo  and  SMC funct iona l  d ivers i ty  in 
the  adu l t  
SMCs from different primary lineages in development are not 
functionally equivalent in vivo. Surgical ablation of the cardiac 
neural crest results in failure to construct an aorticopulmonary 
septum and defects in the organization and propagation of an 
elastin-rich extracellular matrix. 3,1° W11en the cardiac neural crest 
is ablated, surrogate ctomesenchymal SMCs are provided by the 
nodose piacode. However, placode-derived SMCs cannot fully 
compensate for the loss of the cardiac neural crest as seen by the 
developmental defects described above. If both cardiac neural 
crest and nodose placode are ablated, severely malformed aortic 
arch arteries are produced by lateral mesoderm-derived SMCs that 
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are not compatible with survival of the embryo. The important 
point to emphasize is that while three different lineages (cardiac 
neural crest, nodose placode and lateral mesoderm) can produce 
SMCs that occupy the same environment within the developing 
aortic arch complex, each SMC type responds very differently to 
morphogenetic cues operating to direct unica media formation at 
that site. 
Among the important local cues that coordinate cell-cell in- 
teractions in developing arteries are paracrine-acting peptide 
growth factors. Because Mes SMCs cannot compensate for the 
loss of Ect SMCs in cardiac neural crest-ablated mbryos, we 
examined the possibility that these two SMC types differ in their 
ability to respond to one or more exogenous peptide growth 
factors. We found that most of the growth factors tested stimu- 
lated DNA synthesis to similar extents in growth arrested Ect and 
Mes SMCs isolated from ED i4 chick embryo aorta. However, 
when Ect SMCs were exposed to TGF-~31 they exhibited strong 
autoinduction of TGF-61, 132, and [33 gene expression, greatly 
increased PAI-I promoter activity, and enhanced mitogenic re- 
sponses to basic FGF. By contrast, TGF-[31 added to Mes SMCs 
from the same vessels evoked no autoinduction responses, pro- 
duced only minor increases in PAI-1 promoter activity, and 
strongly inhibited the mitogeulc effects of basic FGF. 4 Ect and 
Mes SMCs expressed similar TGF-[3 receptor phenotypes at the 
cell surface, but differ in one or more elements of the downstream 
signal transduction pathways activated by the type I TGF-[3 recep- 
tor (Alk-5). 
Therefore, full understanding of SMC functional diversity in 
the adult will need to consider the effects of SMC lineage back- 
ground on expression ofgenes that control the ability of SMCs to 
respond to various growth factors and cytokines in their local 
environment. 
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IN VITRO MODELS OF BLOOD 
VESSEL ASSEMBLY 
The formation of blood vessels is a complex process, and little is 
known about he individual events that lead to the assembly of a 
quiescent, differentiated blood vessel. The vascular system is 
formed by a combination of vasculogenesis and angiogenesis. In 
vasculogenesis, a primitive vascular network is formed by the 
association of endothelial cell (EC) precursors called angioblasts. 
During angiogenesis, new vessels form by sprouting from existing 
vessels, usually venules. In both cases the vascular tubes undergo 
subsequent remodeling, altering lumen diameter and becoming 
associated with vessel wall cells, smooth muscle cells (SMCs), and 
pericytes. Although some insights have been gained from observa- 
tions and manipulation ofvessel development i  situ, ~,2 the com- 
plexity of the in vivo environment makes it difficult o investigate 
individual events. 
We have, therefore, developed coculture systems to recreate 
various aspects of vessel assembly. We hypothesize that ECs of 
developing blood vessels recruit undifferentiated mesenchymal 
cells to the forming vessels and induce their differentiation into 
SMCs or pericytes, and that these vents are mediated by cell-cell 
interactions and specific growth factors that act in a paracrine 
manner. 
To examine the ability of ECs to recruit undifferentiated 
mesenchymal cells, we have used an underagarose assay. In this 
assay, two cell types are plated into 5 mm wells that are created 2
mm apart in 1% agarose. 10T1/2 cells, multipotent murine em- 
bryo-derived cells, were used as candidates for the SMC/pericyte 
precursors. When ECs and IOT1/2 cells were cocultured for 48 
hours in the underagarose assay, 10T1/2 cells migrated towards 
the ECs in a directed fashion. 3 Inclusion in the agarose of neutral- 
izing antibodies against PDGF-B, but not PDGF-A or bFGF, 
suppressed the EC-stimulated 10T1/2 cell migration. Assessment 
of cell proliferation in the cocultures was accomplished using 
BrdU labeling. 10T1/2 cell growth was increased in the cocul- 
tures; the labeling index of 10T1/2 cells nearest the EC in the 
cocultures (at the front of the well) was twice that of the cells 
furthest away (at the back of the well) or of 10T1/2/cells cultured 
alone. 4 Furthermore, the presence of the PDGF-B but not 
PDGF-A neutralizing antisera totally prevented the increase in the 
labeling index. These results, which implicate PDGF in mesenchy- 
mal recruitment, are supported by earlier observations that ECs of 
developing vessels express PDGF-B while the surrounding mesen- 
chymal cells express the PDGF-[3 receptor, s Furthermore, more 
recent studies have noted an absence ofpericytes in mice deficient 
for PDGF-B ligand. 6 
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In a separate series of studies, we tested the possibility that 
ECs could influence the differentiation f 10T1/2 cells toward a 
SMC/pericyte lineage. Again using the underagarose assay, EC 
and 10T i /2  cells were allowed to coculture for longer times (96 
hours) so the cells would come into physical contact. Immunohis- 
tochemical nalysis revealed that 10T1/2 cells contacting ECs in 
the cocultures had elevated levels of the smooth muscle markers, 
a-SM actin, SM-myosin, and calponin. In addition, 10T1/2 cells 
in coculture with ECs underwent a dramatic shape change from 
rounded, spread morphology to long and spindle shape, reminis- 
cent of the morphology of vascular SMCs in primary culture. To 
quantify this effect, biochemical nalysis was carried out on direct 
cocultures in which EC and 10T1/2 cells were plated simulta- 
neously in a 1:1 ratio into the same dish to maximize cell-cell 
interactions. Western blot analysis revealed a 20-fold increase in 
the level of tx-SM actin and a threefold increase in SM-myosin in 
IOT1/2 cells cocultured with ECs. 
Because of our previous observation that cocultures of ECs 
and mural cells could activate the multifunctional polypeptide 
transforming growth factor beta (TGF-J3), 7 we investigated the 
possibility that TGF-13 might be mediating the induction of the 
SMC/pericyte phenotype. The effect of exogenous TGF-[31 on 
10T1/2 cells was first examined. Addition of TGF-131 to solo 
cultures of 10T1/2 cells led to increased levels of muscle cell- 
specific proteins, as well as changes in cell shape that were similar 
to those observed in cocultures. The role of TGF-f3 in EC- 
10T1/2 cell cocultures was tested by adding, to the underagarose 
assay or the direct co-cultures, a monoclonal antibody that neu- 
tralizes TGF-[3 1, 2 and 3. In the presence of the antisera, there 
was a nearly total suppression of SMC differentiation, with a 95% 
decrease in a-SM actin levels and an 85% decrease in SM-myosin. 
These finding, which point to a role for TGF-J3 in blood vessel 
formation, are supported by observations ofdefective vasculogen- 
esis in mice that lack TGF-J31 s or one of the high affinity TGF-J3/ 
scrine-threonine kinase receptors? In these mice, the contacts 
between the mcsothelial and endodermal layers were unstable, 
leading to dilated vessels with reduced vascular integrity. 
The effect of coculturc on cell proliferation was also exam- 
ined. For this analysis, ECs and 10T1/2 were prelabeled with 
different fluorescent dyes, cocultured for 3 days, and then sepa- 
rated by fluorescent-activated c ll sorting (FACS). The growth of 
both cell types in the cocultures was reduced by 30% to 50% and 
mcdia conditioned by the cocultures was inhibitory for ECs and 
10T1/2 cells grown alone. 4 The molecule(s) that mediate the 
observed growth inhibition are not known, although preliminary 
data indicate that TGF-J3 is not involved in 10T1/2 cell growth 
suppression. 
To confirm that 10T1/2 cells were, in fact, capable of becom- 
ing SMCs in a more complex in vivo environment, the 10T1/2 
cells were prelabeled with a permanent fluorescent dye, seeded 
into a collagen matrix, and then placed either onto the developing 
chick chotioallantoic membrane of 10-day-old fertilized chick 
embryos or implanted subcutaneously into the backs of 6- to 
8-week-old C57 mice. In both cases, the 10T1/2 cells became 
incorporated into the walls of newly developing blood vessels. In 
addition, the incorporated cells stained positively for c,-SM actin, 
whereas 10T1/2 cells incorporated elsewhere into the chick em- 
bryo did not stain for c~-SM actin. 
These studies demonstrate he utility of in vitro analysis for 
dissecting and analyzing the events involved in the formation of 
blood vessels. Our results indicate paracrine roles for the PDGF-B 
and TGF-[3 in blood vessel assembly and further emphasize the 
importance of cell-cell interaction in these developmental pro- 
cesses. The complementary in vivo models will be powerful tools 
to further elucidate the roles and synergistic effects of factors 
found in the in vitro studies to influence vessel assembly. 
Patricia A. D'Amore, PhD 
Children's Hospital 
Harvard Medical School 
Boston, Mass. 
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CELLULAR CROSS-TALK 
CONTROL OF ENDOTHEL IAL  AND SMOOTH 
MUSCLE FUNCTION BY 
EXTRACELLULAR MATRIX 
Recent studies uggest that the extracellular matrix plays not only 
a structural role in tissue homeostasis but provides important 
growth, motility, and survival signals to individual cells through 
specific cell surface adhesion receptors. Growing evidence suggests 
that these signals act in unison with soluble growth regulatory 
molecules to ultimately control cell behavior under various condi- 
tions. Vascular disease is characterized by striking alterations in 
matrix components, both in amount and type, which may contrib- 
ute to lesion formation, vascular remodeling, and ultimately, lumi- 
nal narrowing. Thus extracellular matrix molecules and their re- 
ceptors are considered to be important regulators of vascular cell 
behavior. 
The extracellular matrix molecule on which we have focused 
our attention is osteopontin. Osteopontin is an RGD-containing 
adhesive glycoprotein that has recently been identified as an im- 
portant component of many chronic inflammatory and fibrotic 
diseases, including atherosclerosis and restenosis.10steopontin is 
normally not made by human blood vessels but is produced at 
high levels in both atherosclerotic and restenotic plaques. 2,s Three 
main cell types give rise to osteopontin within the plaque: smooth 
muscle cells, macrophages, and angiogenic endothelial cells. In 
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these lesions, osteopontin is correlated positively with the pro- 
cesses of inflammation, plaque angiogenesis, and calcification. In 
rats, osteopontin expression i arteries occurs after balloon cathe- 
ter endothelial denudation. 3,4 In this model, both smooth muscle 
and regenerating endothelial cells express osteopontin response 
to injury, and expression i  both cell types correlates with prolif- 
eration and active migration of the cells into the denuded region. 
Osteopontin has cell adhesive, migratory, and survival activi- 
ties in vitro for vascular smooth muscle and endothelial cells. 
Endothelial nd smooth muscle cells attach, spread, and form focal 
contacts on osteopontin, suggesting that osteopontin can initiate 
cytoskeletal organization i  both cell types, s,60steoponfin pro- 
motes migration of smooth muscle and endothelial cells in a 
gradient-dependent fashion, s'6 Our most recent studies suggest 
that osteoponfin s an important survival factor for endothelial nd 
smooth muscle cells under diverse conditions. Taken together, 
these properties make osteopontin an interesting candidate for 
participation i the type of tissue remodeling commonly observed 
in vascular lesion development, namely neointima formation. 
Interaction of osteopontin with smooth muscle and endothe- 
lial cells is RGD- and divalent cation-dependent, suggesting that 
integrins are receptors for osteopontin i  these cell types, s,6 In- 
deed, a neutralizing antibody directed against he ~v[33 integtin 
could partially block cell adhesion to osteopontin. However, 
smooth muscle cells lacking ~v[33 also adhere to osteopontin, 
suggesting that additional osteopontin receptors also exist. Using 
specific neutralizing antibodies, we found that osteopontin could 
interact with RvJ31 and c%[3 s on these vascular smooth muscle 
cells. 7 Interestingly, c%[33, C~v[31, and c%[3 sappear to be involved in 
mediating different vascular fimctions of osteopontin. While all 
three receptors can mediate cellular adhesion to osteopontin, ~v[33 
is required for smooth muscle cell migration to osteopontin. The 
concentration of osteopontin sufficient o promote migration in 
c%[33-containing cells ( -30  nmol/L) and the lack of migration in 
oq,131- and c%[3s-containing cells suggests that a signaling mecha- 
nism rather than a simple adhesive gradient isinvolved. In light of 
these findings, it is interesting that both ~[33 and osteopontin are 
colocalized in angiogenic endothellum within human atheroscle- 
rotic plaques, and that C~vJ33 is found in both the medial and 
intimal smooth muscle cells in human coronary arteries. 8 
In addition to cell surface receptors, osteopontin can interact 
with structural extracellular matrix (ECM) molecules uch as fi- 
bronectin and collagen. This has led to the hypothesis that os- 
teopontin may act as an adapter protein capable of bridging the 
cell to its surrounding extracellular matrix. Synthesis of such an 
adapter protein by a migrating cell might enhance that cell's ability 
to interface in a new or remodeling environment. This might be 
particularly important for a smooth muscle cell invading the neo- 
intima or an angiogenic endothelial cell penetrating an ischemic 
tissue or tumor. For the adapter function to be possible, however, 
cell surface binding and ECM binding regions must be located in 
distinct regions of the osteopontin molecule. To examine the 
structure/function relationships ofosteopontin, we have created a
series of recombinants o teopontin proteins, and peptides. Muta- 
tion or deletion of the RGD sequence in the full-length osteopon- 
tin molecule abolishes cell adhesive and migratory activity, 6 con- 
firming that the RGD domain is required for interaction with 
c~-containing integrins. Fragmentation of osteopontin into the 
N-terminal or C-terminal halves that arise after thrombin cleavage 
led to enhanced cell adhesive and migratory activity, which was 
completely contained in the N-terminal fragment. 9 Unexpectedly, 
this fragment also bound to human melanoma cell lines which 
failed to bind to the full length osteopontin molecule, suggesting 
a thrombin-dependent switch in receptor specificity. The binding 
of human melanoma cells to osteopontin was cx9[31-dependent a d 
only poorly inhibited by RGD. Additional studies uggest that the 
full-length osteopontin contains acryptic site which is exposed on 
thrombin cleavage to reveal c~ 9131-binding activity. The location of 
the cryptic site is not yet known. 
To investigate the potential contribution of osteopontin to 
vascular disease in vivo, we developed a polyclonal antibody that 
specifically neutralizes rat osteopontin, s This antibody, or a non- 
immune control antibody, was infused into rats after balloon 
catheterization f the left carotid artery. A 33% decrease was 
observed in neointimal area in the antiosteopontin group after 2 
weeks. A decrease in the total number of cells in the intima and no 
change in gross matrix suggested that the decrease in the neoin- 
tima might be due to blocking of SMC migration into the intima. 
This was supported by a second study that showed no significant 
difference in early medial or late intimal SMC proliferation rates in 
the antiosteopontin- or control antibody-treated rats. These stud- 
ies demonstrate for the first time a functional role for osteopontin 
in the process of carotid neointimal thickening in vivo and suggest 
that osteopontin plays an active role in the remodeling processes 
important for human atherosclerotic and restenotic lesion devel- 
opment. 1° 
Cecilia M. Giachelli, PhD 
University of Washington School of Medicine 
Seattle, Wash. 
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REGULAT ION OF ENDOTHEL IAL  GENE 
EXPRESSION BY BLOOD FLOW 
Vascular endothelium, the single-cell-thick lining of the cardiovas- 
cular system, is a dynamically mutable interface that can exhibit a 
spectrum of adaptive changes in response to physiologic and 
pathophysiologic stimuli. It produces an impressive repertoire of 
biologic response modifiers (e.g., EDRF/NO, prostacyclin; vari- 
ous growth factors and cytokines; coagulation and fibrinolytic 
factors), many of which contribute to agonist/antagonist balances 
that have important implications for the function of the vascular 
lining, adjacent smooth muscle cells, and interacting blood con- 
stituents. 1 
Because of its unique anatomic position, the endothelial lin- 
ing of the heart and blood vessels is constantly exposed to various 
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types of hemodynamic forces, such as hydrostatic pressure, cyclic 
strain, and wall shear stress, generated by the pulsatlle flow of 
blood. 2There is increasing evidence that these stimuli are trans- 
duced by the endothelial cell into responses that can have both 
adaptive and nonadaptive consequences. Evidence of the effect of 
hemodynamic forces on endothelinm is apparent from simple 
morphologic examination of the intimal surface of normal ves- 
sels-when viewed en face endothelial cells in the tubular portions 
of the arterial tree, which characteristically have a (time-averaged) 
steady laminar flow pattern, exhibit an ellipsoidal shape and are 
coaxially aligned in the direction of blood flow, whereas near 
branch points and in areas of marked curvature (e.g., the aortic 
arch) the shape of individual cells is more polygonal and lacks any 
particular orientation, consistent with the local disturbed flow 
pattern, a In a physiologic ontext, the structural remodeling of 
arteries observed in response to chronic changes in blood flow 
reflects a dynamic balance of events, including cell proliferation 
and cell death (apoptosis), aswell as extracellular matrix synthesis 
and degradation, many of which appear to be endothelium-depen- 
dent. 4 In a pathologic ontext, the nonrandom distribution of 
early atherosclerotic lesions that is observed both in the natural 
disease process in humans and in various experimental nimal 
models has been cited as suggestive evidence of a role for hemo- 
dynamic forces in disease pathogenesis, although the exact nature 
of the responsible fluid mechanical factors (high vs low wall shear 
stresses, flow disturbances, stagnant boundary layer) has long been 
an area of debate, s Recently, much attention has been focused on 
the cellular and molecular mechanisms that underly the response 
of endothelium tofluid mechanical stimuli. 
In collaboration with Prof. C. F. Dewey (Fluid Mechanics 
Laboratory, Massachusetts Institute of Technology), our labora- 
tory has designed in vitro fluid mechanical systems to expose 
cultured endothelial monolayers to defined stimuli, such as lami- 
nar, disturbed laminar, and turbulent flow. 6,7 Initially using the 
human PDGF-B chain gene as a model, we investigated the 
genetic regulatory mechanisms involved in flow-induced gene 
expression i endothelium. 8 Steady-state PDGF-B mRNA levels 
were increased several fold by brief exposure to physiologic levels 
of laminar shear stress (10 dyne/cm2; 4 hours). Transfection of 
reporter gene constructs, based on nested eletional mutations of 
the PDGF-B promoter, documented transcriptional upregulation 
and localized a "shear-stress-response element (SSRE)" that ap- 
peared necessary for the shear-inducibility of this gene. Electro- 
mobility shift assays identified a 6 bp core element (GAGACC) 
that formed specific complexes with nuclear proteins extracted 
from endothelial monolayers a early as 30 minutes after the onset 
of flow. This rapid nuclear protein-DNA binding event was con- 
sistent with the kinetics of transcriptional activation of the intact 
PDGF-B gene as demonstrated by nuclear run-off analysis. Collab- 
orative studies with Dr. T. Collins' laboratory (Department of 
Pathology, Brigham and Women's Hospital) have demonstrated 
that he SSRE motif present in the PDGF-B gene can interact with 
components of the NF-kB system of transcription factors? The 
latter can be visualized by immunofluorescence microscopy, to 
translocate from the cytoplasm to the nucleus within 10 minutes 
after application of a shear stress timulus.l° 
In addition to the SSRE motif identified in the human 
PDGF-B gene, recent studies have also pointed to the existence of 
other positive (and negative) shear stress response lements in 
other pathophysiologically important genes. For example, Shyy et 
al.n have implicated a TRE (AP-1 family) site in the upregulation 
of the monocyte chemotactic protein-1 (MCP-1) gene by shear 
stress. In the case of the PDGF-A gene, which is shear-responsive, 
but lacks the GAGACC motif defined in the PDGF-B gene, our 
group has recently demonstrated a functional interaction of the 
early growth response-1 (Egr-1) protein with binding sites in the 
proximal PDGF-A promoter; interestingly, the gene encoding 
Egr-1 is induced by shear stress32 Finally, Ando and coworkers 13
have defined a "negative SSRE" in the VCAM-1 promoter that 
appears to mediate the transcriptional downregulation f this gene 
in endothelial cells in response to laminar shear stress. 
To gain a better appreciation of the patterns of endothelial 
genes that are differentially regulated by distinct ypes of biome- 
chanical and biochemical stimuli, we have recently undertaken a 
new experimental strategy. In collaboration with Dr. D. Falb's 
group at Millennium Pharmaceuticals Inc. (Cambridge, Mass.), 
we are using a RT-PCR-based, high-throughput, differential dis- 
play of expressed transcripts osystematically compare the patterns 
of genes that are upregulated or downregulated in cultured hu- 
man endothelial cells in response to a physiologic level of steady 
laminar shear stress (LSS), a comparable vel of turbulent shear 
stress (TSS), and a standard cytokine (IL-1) stimulus. Our prelim- 
inary results indicate that LSS elicits a unique pattern of endothe- 
lial gene expression, consisting of both known and novel genes, 
that is not observed by TSS or IL-134 The physiologic actions of 
certain of the known genes, which include the endothelial isoform 
of nitric oxide synthase, cNOS; the inducible isoform of cyclo- 
oxygenase, COX-2; and Mn-SOD, an important intraceliular 
antioxidant enzyme, suggests that these genes may be playing a 
"vasoprotective" or "antiatherogenic" role. Their selective and 
sustained upregulation by steady laminar shear stress, the hemody- 
namic stimulus typically encountered by endothelial cells in the 
lesion-protected areas of the arterial tree, is consistent with tlxis 
premise. We are currently testing this working hypothesis invari- 
ous in vitro and in vivo models. 
Michael A. Gimbrone, Jr., MD 
Brigham and Women's Hospital 
Boston, Mass. 
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CONTROL OF ENDOTHEL IAL  CELL FUNCTION 
BY WALL STRESS 
Endothelial cells are subjected to various mechanical forces in vivo 
from the pulsatile flow of blood across the luminal surface of the 
blood vessel. The purpose of this presentation is to examine the 
data available on how these mechanical forces affect he expression 
and regulation of endothelial cell function by using the paradigm 
of repetitive distension. Studies from various investigators u ing 
models of cyclic strain in vitro have shown that various genes are 
induced by the effect of mechanical deformation, and that the 
expression of these mediators may be regulated at the transcrip- 
tion level by mechanical forces. There also seems to be emerging 
evidence that endothelial cells may also act as mechanotransduc- 
ers, whereby the transmission of external forces induces various 
cytoskeletal changes and second messenger cascades. 
Studies on animals have shown that the aortic wall is repeti- 
tively distended as much as 30% during the pulsatile flow of 
blood? Recent studies on vessel wall tone suggest that there is an 
underlying positive residual strain pattern in the vessel wall in fresh 
cadaveric specimens? The amount of estimated residual strain 
varied depending on the site along the length of the aorta, but was 
as much as 10%. 
Our previous work has demonstrated that endothelial cells 
respond to cyclic strain with an increase in proliferation 3 and with 
a change in morphology 4 and migration, s Furthermore, we have 
also reported that endothelial cells exposed to cyclic strain express 
and release significant amounts ofvasoactive compounds, includ- 
ing tissue plasminogen activator, 6 endothelin, and nitric oxide. 7 
However, the mechanisms by which the cells sense and respond to 
physical forces remain undetermined. The major impetus in the 
field has heen to define the "mechanosensor(s)" on the cells that 
are sensitive to the different external forces, as well as the coupling 
ofintracellular pathways and the subsequent uclear events which 
precede the cell response. 
The role of the endothelium in the control and regulation of 
the vascular system has become increasingly obvious as studies are 
done to examine the signaling pathways involved in the expression 
of endothelial cell function. Cells that were once thought of as just 
lining for blood vessels have taken on a significance that belies 
their seemingly simple structure. Their potential role as mechano- 
transducers now seems more likely. As they are subject o repeti- 
tive stretch, endothelial cells are capable of altering their cytoskel- 
etal structure and mechanical properties in a pattern different o 
that seen in endothelial cells subjected to shear stress. The alter- 
ation of the structure by mechanical forces also produces changes 
in their internal cellular tensions. These external forces therefore 
create adirect ransmission of force internally which may result in 
activation of sensors at the cell surface and at anchorage points 
such as the focal adhesion plaques. 
At the site of attachment ofendothelial cells to their underly- 
ing extracellular matrix, there are dense accumulations known as 
focal adhesion plaques. Davies and others have postulated that 
endothelial cells act as mechanotransducers by responding to the 
transmission of forces via the activation of focal adhesion mole- 
cules such as paxillin, talin, and focal adhesion kinase (FAK) in 
these plaques,  Ingber and coworkers 9 have also proposed that 
cells are in a preexisting state of force equilibrium (tensegrity 
model) in which cells exert tension on their extracellular ttach- 
ments. A shift in force equilibrium resulting from an external 
mechanical load would lead to redistribution of forces to the 
cellular attachments, which are the focal adhesion molecules. They 
therefore postulate that focal adhesion molecules may play a role 
in coupling mechanical stress to biochemical signaling. They have 
also shown evidence that integrins may act as mechanotransducers 
by linking acfin filaments to the extracellular matrix via focal 
adhesion molecules such as paxillin and FAK. 
Our laboratory has studied the effect of cyclic strain on the 
activation of focal adhesion molecules and integrin recruitment. 
We have noted increased tyrosine phosphorylation f focal adhe- 
sion molecules FAK and paxillin and the involvement ofthe small 
GTP-binding protein, rho in endothelial cells exposed to 
strain, s,l° The induction ofFAK phosphorylation ccurred as early 
as 30 minutes of strain. We have also observed that strain induces 
a redistribution of FAK and paxillin and the integrins, n Tyrosine 
kinase inhibition resulted in not only a diminished level of phos- 
phorylation and redistribution ofFAK and paxillin, but also a loss 
in the morphologic hange and migration of endothelial cells 
induced by strain. This suggests that phosphorylation f certain 
focal adhesion proteins play an important role in the morphologic 
change and enhanced migration seen in endothelial cells subjected 
to cyclic strain. 
The identity of sensors at the cell surface, if they exist, are not 
known. It has been posited that mechanosensitive on channels 
and G-proteins may be involved. Activation of mechanosensitive 
Ca ++ ion channels 12 leading to an influx of Ca ++, has been 
postulated to lead to second messenger cascades such as activation 
of protein kinase C pathways responsible for the production of 
some of the vasoactive molecules produced by endothelial cells. 
Some endothelial cell responses to physical stimuli have been 
shown to be dependent on G-protein activation, and recent evi- 
dence suggests that cyclic strain can activate certain G-proteins.~3 
We have also reported the activation of phospholipase C as evi- 
denced by generation ofinositol 1,4,5 triphosphate (IP3), 14,15 and 
diacylglycerol (DAG) ~6 in endothelial cells subjected to cyclic 
strain which also suggests, albeit indirectly, the presence of G- 
protein activation. 
A variety of second messenger metabolic pathways are also 
activated by mechanical forces. For example, cyclic strain leads to 
activation of protein kinase A/adenylate cyclase, ~7 thereby increas- 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 6 Special Communication 1095 
ing intracellular cyclic AMP, which is also accompanied by an 
increased binding of the nuclear factor CRE. is We have also 
reported that the phosphoinositide pathway is activated in ECs 
subjected to cyclic strain with the production of IP3 and DAG 14 
and activation of PKC 19 within seconds of the initiation of cyclic 
strain. Furthermore, the induction of certain fos and jun mRNA 
occurred by 30 minutes, and levels of the transcription factor AP- 1 
increased by 4 hours after cyclic stra in.  2° Duet  al. studied the 
effect of cyclic strain on other transcription factors, is In human 
umbilical vein endothelial cells, 4 hours of 10% average strain at 60 
cycles/min induced a 22-fold increase in AP-1 and also a fivefold 
increase in NF-kB levels compared with control as measured by gel 
shift analysis. CRE induction occurred as early as 15 minutes with 
a twofold increase and at 24 hours with a fourfold increase. 
Although these results show gene and transcription factor 
induction, they do not prove that cyclic strain directly induces 
promoter geue activation. To show a direct effect of cyclic strain 
on gene transcription, one would have to show the presence of 
responsive lements in the promoter region that are directly and 
specifically induced by strain. To elucidate the exact mechanism by 
which cyclic strain induces gene expression, our laboratory has 
embarked on studies looking at the promoter region of genes that 
are responsive to strain to determine whether there is a consensus 
sequence that specifically modulates the cyclic strain effect. Using 
promoter-reporter g ne constructs, bovine aortic endothelial cells 
can be transiently transfected and promoter activity assayed after 
exposure of the endothelial cells to cyclic strain. Deletion con- 
structs of these genes can then determine where important regions 
exist, and further promoter analysis with point mutations can 
determine specific responsive lements. Using this technique, 
Resnick et al. have discovered a putative shear stress response 
element (SSRE) in the promoter region of PDGF. This sequence 
(GAGACC) and its complementary sequence has been noted in 
other genes that are responsive to shear stress. 21 In collaboration 
with Resnick and coworkers, we have recently demonstrated that 
the SSRE may also play a significant role in the regulation of cyclic 
strain sensitive genes. Endothelial cells subjected to an average of 
10% cyclic strain at a frequency of 60 cycles/min for up to 24 
hours showed specific binding of the SSRE probe as early as 30 
minutes, suggesting that cyclic strain induced activation of 
SSRE. 22 Although binding is demonstrated, this does not neces- 
sarily imply that it is functional. Promoter studies using constructs 
containing mutations of SSRE will be needed to determine the 
significance of the observed binding. 
In conclusion, it is clear that physical forces can exert signifi- 
cant influence on the cells in the blood vessel wall. The importance 
of in vitro studies lies in understanding how mechanical forces in 
vivo modulate the expression of endothelial cells, and should help 
in better formulating therapy aimed at vascular disease processes 
such as hypertension, atherosclerosis, and disorders of the throm- 
bolytic pathway. 
Bauer E. Sumpio, MD, PhD 
Yale University School of Medicine 
New Haven, Conn. 
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VASCULAR ADAPTAT ION DURING 
GROWTH AND DEVELOPMENT AND IN  
D ISEASE STATES 
INFLUENCE OF  BLOOD FLOW ON NORMAL 
ARTERIAL  DEVELOPMENT 
Tissues in the healthy, mature artery wall are usually quiescent: cell 
replication rates are typically much less than 1% per day and 
synthesis (turnover) rates for the major extracellular constituents, 
elastin and collagen, for example, are extremely low. In contrast, 
the developing artery wall continuously remodels to accommodate 
the changing demands for blood flow of developing peripheral 
tissues and the changing blood pressures that are required to drive 
these flows. Available evidence indicates that this remodeling is 
regulated by a direct sensitivity of arterial tissues to shear stress and 
tensile stress, the physical forces associated with blood flow and 
blood pressure, respectively. This presentation focuses on the 
sensitivity of developmental rterial remodeling to shear stresses 
imposed on the endothelial surface of the vessel wall. 
Prenatal and perinatal arterial remode l ing  
Thoma 1 first proposed that sensitivity to developmental 
changes in blood flow regulates the earliest development of the 
circulation, and Clark 2 later speculated that the "blood flow over 
the endothelinm" may be the stimulus for growth modulation. 
This sensitivity of arterial development to blood flow persists at 
later stages of development. The perinatal period is particularly 
instructive in this regard, because very large and abrupt changes in 
blood flow distribution occur at parturition. 3 A dramatic example 
is the more than 90% decrease in blood flow observed in the 
subrenal abdominal aorta, subsequent to loss of placental perfu- 
sion, which is accompanied by a marked reduction in diameter of 
the vessel and a near arrest of wall tissue accumulation that lasts for 
weeks. Other arteries also display growth modulation that corre- 
lates with blood flow in this period. In particular, elastin accumu- 
lation in early postpartum life correlates with blood flow changes 
at birth. 4 The sensitivity of elastin to changes in blood flow rate is 
not surprising because lastin bears much of the tensile load at 
resting blood pressures; therefore it is a primary determinant of  
normal vessel dimensions and consequently considerable r mod- 
eling of elastin is necessary to change vessel geometry. 
Postnatal arterial growth 
During postnatal growth and development, both smooth 
muscle and elastin accumulation are affected when flows are ma- 
nipulated in the subnormal range. When 70% reductions in com- 
mon carotid blood flows were induced in weanling rabbits by 
ligating the external carotid artery, DNA and elastin contents were 
substantially below those of control vessels 1 month later, s How- 
ever, smooth muscle content becomes relatively insensitive to 
flows that are above normal evels, whereas elastin accumulation 
continues to be affected. Twofold increases in carotid blood flows 
caused by contralateral common carotid ligation, again in young 
rabbits, results in a 50% elevation in elastin accumulation while 
changes in DNA content are insignificant (Di Stefano and Lang- 
ille, unpublished ata). 
Endothelial sensitivity to shear stress: the way endothelium 
senses hear stress is not well understood. Focal adhesions are 
potential sites of shear stress transduction by endothelium because 
shear forces exerted on the apical surfaces of the cells are transmit- 
ted to these basal attachment sites, and there is evidence for 
shear-induced phosphorylation of proteins concentrated at focal 
adhesion sites, specifically paxillin 6 and focal adhesion kinase. 7
Tyrosine phosphorylated FAK or paxillin can link to signal trans- 
duction proteins via SH2 (src homology type 2) domains of the 
latter, therefore providing a possible link between focal adhesion 
complexes and cellular responses to shear. Recent evidence for 
shear-activation f  MAP (mitogen-activated protein) kinase s pro- 
vides one potential pathway for such signaling. Other putative 
mechanisms of shear transduction i clude shear-sensitive potas- 
sium channels, which appear important in regulating TGF-[3 ex- 
pression, 9 and shear-dependent mass transport of ATP to puriner- 
gic receptors on endothelium. 1° 
How sensitivity to shear stress regulates arterial remodeling is
not straightforward. It is commonly argued that, after flow pertur- 
bations, simple feedback control of  remodeling restores hear 
stress to a control evel of  around 10 dynes/era 2. However, pre- 
vailing shear stress in arteries are vessel-specific, species-specific, 
and age-specific. In general, shear stresses are higher in smaller 
individuals; for example, shear stresses in regions of the rat aorta 
that are not near branch sites are probably 30 to 50 dynes/cm 2.
This effect is accentuated during development because of the high 
metabolic demands of tissue synthesis. It is of  interest, for exam- 
ple, that shear stresses in umbilical veins, a common source ofceUs 
for endothelial cells for culture, are approximately 30 to 40 dynes/ 
cm 2, because of the high flows delivered to the placenta during 
fetal life. 
Flow-related remode l ing  o f  ext race l lu la r  mat r ix  
Elastin accumulation is highly sensitive to increases or de- 
creases in blood flow rate through developing arteries. Sensitivity 
of elastin synthesis n large arteries to hemodynamic stresses i not 
surprising, because remodeling in response to these stresses 
changes the basic geometry of the vessel wall, and this geometry is
sensitive to elastin content and organization because lastin bears 
much of resting wall tension. Consequently, remodeling of elastin 
probably is a prerequisite for producing large changes in resting 
arterial dimensions. However, the local mechanisms that translate 
mechanical forces into regulation of elastin production are poorly 
understood. Elastin expression is modulated by cortisol, 11 insulin- 
like growth factor-1 (IGF-I), 12 and transforming growth factorq3 
(TGF-[3). 13 
Precisely how elastin is reorganized uring remodeling of 
large arteries raises intriguing questions because this protein is laid 
down essentially in complete cylindrical shells within the vessel 
wall. Work by Davis 14 indicates that newly synthesized elastin 
accretes onto the inner and outer surfaces oflamellae, with prefer- 
ential deposition occurring near the fenestrae that frequently per- 
forate the lamellae. Such accretion could account for lamellar 
thickening during normal development but not for changes in 
lamellar circumference. However, recent data indicate that alter- 
ations to the fenestrae that perforate lamellae are important in the 
remodeling of these structures. Fenestrae increase greatly in size 
and number during postnatal growth despite rapid accumulation 
of new elastin and despite vidence that newly synthesized elastin 
is deposited preferentially at fenestrae. ~4 Also, experimental in- 
creases and decreases in blood flow rate substantially influenced 
the size of fenestrae in lamellae of  developing arteries. The picture 
that emerges i oflamellar thickening proceeding through deposi- 
tion of new elastin onto the inner and outer surfaces of lamellae 
and lamellar circumference (and length) increasing through for- 
mation of fenestrae, with both processes being sensitive to hemo- 
dynamic stresses. 
In contrast to elastin, synthesis and accumulation of collagen 
is surprisingly insensitive to changes in blood flow rate, at least 
after birth. We found that neither large reductions nor large 
increases in blood flow rate affected total collagen accumulation i
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immature experimental nimals. It remains possible that flow 
modulation has a large eREct on the relative amounts of different 
types of collagen found in arteries without affecting total collagen 
types, but the significance of such an effect, if it occurs, is uncer- 
tain. 
There is no evidence pertaining to flow-induced changes in 
other matrix constituents, notably proteoglycans orglycoproteins, 
some of which may be particularly important in regulating smooth 
muscle and endothelial cell functions as remodeling proceeds. 
Cell proliferation and cell death in arterial 
remodeling 
Physiologic and developmental remodeling of tissues gener- 
ally is achieved by resident cell types; therefore, control ofinttinsic 
cell populations i vital to appropriate r modeling responses. Until 
recently, it has been implicitly assumed by many that vascular cell 
populations were controlled entirely by regulation of cell prolifer- 
ation rates. However, Cho et al. is recently demonstrated that 
apoptotic ell death participates in neonatal remodeling of central 
arteries. New data implicate apoptosis in flow-related remodeling 
at later postnatal development. For example, 70% decreases in 
blood flow rate in carotid arteries of 3-week-old rabbits upregu- 
lated apoptosis by threefold; in addition, cell proliferation rates 
were suppressed by 75% to 95%. Enhanced apoptosis and sup- 
pressed cell replication were observed for both endothelial and 
smooth muscle cells. Fractional rates of apoptosis and replication 
indicate that both were important in remodeling. Thus cell death 
rates went from less than to greater than proliferation rates when 
flow was suppressed. 
Stmunary 
Cell proliferation, cell death, matrix synthesis, and matrix 
remodeling all participate in developmental remodeling of arter- 
ies, and each of these processes i sensitive to changes in blood 
flow rate through the vessel lumen. New insights have been gained 
concerning this remodeling; however, no unified picture has 
evolved concerning how developmental remodeling is controlled 
by local hemodynamics. 
B. Lowell Langille, PhD 
Toronto Hospital 
Toronto, Ontario, Canada 
The author is a Career Investigator of the Heart and Stroke 
Foundation of Ontario. 
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ATHEROSCLEROSIS  PROGRESSION AND 
VASCULAR ADAPTAT ION 
Our classical concepts of progression of atherosclerosis envisaged 
progressive insudation of lipids and an ensuing tissue reaction. 
These processes would lead inexorably to critical narrowing of the 
affected artery, yielding anginal syndromes and eventually coro- 
nary occlusion with myocardial infarction. Increasing acuity of 
clinical and pathologic observations and the flourishing of vascular 
biology have hand-in-hand substantially revised this view. Con- 
vincing new clinical data have emerged from serial angiographic 
studies over the last decade: (1) studies of the angiographic sub- 
strate underlying acute myocardial infarction have shown that 
noncritical lesions often produce the acute coronary syndromes~; 
in part, this results from compensatory enlargement of the artery 
during atherogenesis, a form of adaptive remodeling; (2) lipid- 
lowering trials have shown scant reductions in angiographic steno- 
ses, but consistent and substantial reductions in coronary 
events2,S; and (3) coronary stenoses often progress episodically 
rather than gradually and continuously. 4 
Pathologic studies of the microanatomy of fatal coronary 
lesions have shown that physical disruption of plaques (often not 
highly stenotic lesions) usually furnish the nidus for thrombotic 
coronary occlusion, s The disruption most commonly involves a 
fracture of the plaque's fibrous cap, overlying the lesion's lipid 
core, but may also involve a superficial erosion of the intimal 
surface. 6 Once the lesion's integrity is breached, thrombosis usu- 
ally ensues due to contact of the blood with the thrombogenic 
tissue factor-rich lipid core and/or collagen in the subendothe- 
lium. When nonocclusive and rapidly lysed or healed, the throm- 
bus may be clinically silent or cause an episode ofischemia t rest. 
When occlusive and propagated or sustained, acute myocardial 
infarction may result. In either case, activation of thrombin and 
associated products of thrombosis including platelet-derived :f'ac- 
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tors can evoke a round of smooth muscle proliferation and pro- 
mote fibrosis, leading to lesion progression and complication. 
Features of plaques that have ruptured includeS,7: (1) a thin 
fibrous cap; (2) a large lipid pool; (3) abundant macrophages and 
T lymphocytes; (4) a paucity of smooth muscle cells; and (5) signs 
of inflammatory activation of arterial cells and infiltrating leuko- 
cytes. 
Interestingly, the artery remodels by growing outward to 
accommodate he developing intimal lesion. This represents an 
adaptive form of vascular emodeling that preserves the lumen 
caliber to retain perfusion. However, this compensatory enlarge- 
ment does render the angiogram falsely reassuring, as lesions 
biologically prone to rupture and causing thrombosis may appear 
innocent by traditional angiographic criteria. 
We have recently explored the molecular mechanisms that 
link morphologic characteristics of vulnerable atherosclerotic 
plaques with their biologic behavior, s There are at least three 
distinct mechanisms that influence the composition of the extra- 
cellular matrix that confers the structural integrity on the plaque's 
fibrous cap. 
(1) Impaired extracellular matrix synthetic ability in regions of 
plaque rupture. The cytoldne gamma-interferon produced by le- 
sional T cells strikingly inhibits interstitial collagen gene expres- 
sion by human smooth muscle cells in culture. 9 This lympholdne 
can account for the signs of inflammation documented atsites of 
plaque rupture and impair the ability of smooth muscle cells to 
repair and maintain the collagen that confers strength on the 
plaque's fibrous cap. 
(2) Increased extracellular matrix degradation i regions of 
plaque rupture. Inflammatory cytokines present in atheroma can 
stimulate human vascular smooth muscle cells to express the genes 
that encode metalloproteinases that can break down collagen, 
such as interstitial collagenase, gelatinases, and stromelysin, in a 
regulatable fashion.I° We have further found that lipid-laden mac- 
rophages from the aorta of rabbits express interstitial collagenase 
and stromelysin,  Human lesions also show expression of these 
proteases insmooth muscle cells and macrophages. 12,1a The action 
of these matrix-degrading enzymes may contribute further to 
weakening of the atherosclerofic plaques fibrous cap. 
(3) Death of smooth muscle cells in regions of plaque rupture. 
In addition to inhibiting collagen synthesis, gamma interferon can 
halt the proliferation of smooth muscle cells and, in combination 
with other cytokines uch as interleukin-1 and/or tumor necrosis 
factor c~, can induce programmed cell death in these cells. 14 Re- 
cent studies have established that smooth muscle cells within 
human atherosclerofic lesions bear markers of apoptosis. Is,16 
These results establish that death of smooth muscle cells may also 
contribue to the paucity of these collagen-producing cells in vul- 
nerable regions of human atherosclerofic plaques. 
Clinical implications 
We believe that these observations have several important 
clinical implications. First of all, they furnish insight into how lipid 
lowering can reduce clinical manifestations ofatheroma to a much 
greater extent han they produce angiographic regression of ste- 
notic lesions. We hypothesize that the clinical benefit of lipid- 
lowering therapies on acute coronary events derives from an "an- 
tiinflammatory" effect. Removing the lipids from lesions may 
stabilize them by reducing cytokine xpression that drives all three 
mechanisms promoting plaque vulnerability listed above. This 
process need not necessarily entail a substantive reduction in 
luminal caliber. 
In addition, the new-found evidence for involvement of in- 
flammatory pathways in complications of athersclerosis indicates 
novel potential targets for therapeutic intervention and new ways 
of thinking about he clinical activity ofatheroma. Pursuit of these 
targets hould help us understand the biology of the manifesta- 
tions ofatherosclerosis we see as clinicians. The synthesis of studies 
conducted by clinicians, pathologists, and vascular biologists has 
provided anew view of the acute coronary syndromes that would 
have remained obscure without joining the insights from each 
discipline. These changing concepts hould yield novel inroads 
into stabilizing atherosclerotic lesions and reducing clinical events 
in our patients in the future. 
Peter Libby, MD 
Brigham and Women's Hospital 
Harvard Medical School 
Boston, Mass. 
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HEAL ING AND ADAPTAT ION IN  
ARTERIAL  REPLACEMENTS 
VE IN  GRAFT ADAPTAT ION IN THE 
ARTERIAL C IRCULAT ION 
Autogenous vein remains a constant source of bypass conduit for 
revascularization. The universal response of vein grafts to their 
insertion into the arterial circulation is the development ofintimal 
hyperplasia, which develops within 2 years of implantation. Up to 
30% of vein grafts will require intervention within 2 years due to 
the development of hemodynamically significant intimal hyper- 
plastic lesions (graft stenoses). Intimal hyperplasia s a lesion com- 
posed of smooth muscle cells interspersed with a connective tissue 
matrix and covered on the luminal aspect by confluent endothelial 
cells. The development of intimal hyperplasia begins early after 
surgery with the stimulation of smooth muscle cells to migrate 
from the media of the vessel into the intima and once there, to 
proliferate. Thereafter, the cells lay down a complex extracelhilar 
matrix. Histologic examination of excised areas of human vein 
graft stenoses demonstrates that these lesions are highly cellular, 
composed predominantly of smooth muscle cells. In animal mod- 
els of vein graft intimal hyperplasia, the lesion is also highly cellular 
and is thus comparable with the early lesions observed in human 
beings. However, one caveat must be applied--the degree of 
luminal compromise in animal models is often not as significant as 
that seen in many human vein grafts. The actual stimuli which 
initiate the intimal hyperplastic process are poorly defined. The 
medial smooth muscle cells suffer a degree of injury as a result of 
the operative procedure, subsequently he endothelium ofthe vein 
graft becomes dysfunctional ( osing its ability to produce NO- 
mediated relaxation to several agonists), and the vessel is exposed 
to a range of hemodynamic, ellular, and humoral factors. All of 
these events may evoke the characteristic early smooth muscle cell 
migration and proliferation. 
Hemodynamic alterations are implicated in the intimal re- 
sponse of vein grafts. Recent evidence suggests that deformation 
of smooth muscle cells by arterial hemodynamics an lead to 
activation of protein tyrosine kinases and thereby initiate smooth 
muscle cell proliferation. In vein grafts, blood flow (closely associ- 
ated with shear stress) is best associated with the formation of 
intimal hyperplasia, whereas deformation of the vessel wall in a 
circumferential direction is best associated with medial hypertro- 
phy. Vein grafts with lower flows, increased wall tension, or lower 
shear stresses are associated with the development of greater inti- 
mal hyperplasia. Similarly, accelerated intimal hyperplasia develops 
in vein grafts with poor distal runoff(low flow conditions) and this 
can be reversed when these vessels are reimplanted into a system 
with normal parameters of flow. Several studies have shown that 
rigid external support of a vein graft that mitigates mechanical 
stresses will reduce the development ofintimal hyperplasia. 
Experimental nd angioscopic studies have demonstrated that 
the endothelium of a vein graft is preserved after implantation. 
Vein grafts do experience a generalized type I and II endothelial 
injury, in addition to focal type III lesions at the anastomoses or in 
areas of injudicious manipulation. Current studies have demon- 
strated that after exposure to the arterial environment, the cells 
experience s vere stretching and increased tangential stress both of 
which contribute to endothelial cell injury. Within 24 hours, the 
endothelial ceils are sandwiched between adherent luminal and 
infiltrating subendothelial polymorphonucleocytes with platelet 
deposition on the endothelial surface and extensive subendothelial 
edema. In experimental vein grafts, smooth muscle cell prolifera- 
tion occurs within the first 72 hours and continues for at least 7 
days after insertion. Microscopic development ofintimal hyperpla- 
sia occurs from day 3 to 5, increases rapidly between 7 to 14 days, 
and stabilizes by day 28. Histologic surveys of human saphenous 
vein grafts show focal loss of endothelial cells, particularly at the 
perianastomotic areas, and fibrin deposition on the intima in the 
early postoperative p riod (<24 hours). During the following 4 
days, the deposition of intimal fibrin and the accumulation of 
various blood cell elements on the endothelial surface become 
more prominent. By days 7 to i4 the endothelial cell layer in 
human grafts can be redefined, and at this time intirnal hyperplasia 
can be identified. 
The precise initiating stimuli for inrimal hyperplasia have not 
been fully defined, but it appears to be the response of the vascular 
smooth muscle cells to a combination of physical, cellular, and 
humoral factors accompanied by dysfunctional endothelial regula- 
tion. The relationship of endothelial cell structure and function 
with the development of intimal hyperplasia is well recognized. 
Fibroblast growth factors contribute significantly to the medial 
proliferation of smooth muscle cells, while the presence of either 
endogenous or exogenous platelet-derived growth factors pro- 
mote the migration of smooth muscle cells from the media to the 
intima. Several other mediators of both the tyrosine kinase 
(IGF-1, TGF-c~, c~-thrombin, and interleukln-ll3) and G-protein 
(angiotensin II, endothelin-1, serotonin, adrenergic) coupled 
membrane receptors have been shown to participate in these 
initial events. The mediators of the intimal proliferative re- 
sponse that occurs after migration from the media are unclear, 
as are the factors that induce smooth muscle cell proliferation 
to wane and the synthesis of extraceUular matrix to begin. 
There are suggestions that the activity of transforming growth 
factor-J3 isoforms and endothelial cells are important in this 
transition from an "activated" state to a relative "quiescent" 
state. Little apoptosis can be identified in early experimental 
vein grafts. Primary cultures from vein graft stenotic lesions 
have suggested that the smooth muscle cell phenotype present 
is more resistant o the action of growth inhibitors such as 
heparin than other areas of the graft. 
For a cell to respond to its environment, i  must be able to 
sense the stimuli, transduce the signals across the membrane, 
activate a secondary messenger, and translate these second mes- 
sages to produce an intracellular response. The key links in the 
signal transduction pathway are guanine nucleotide regulatory 
protein (G-protein) and protein tyrosine kinase-coupled recep- 
tors. Activation of these two pathways results in a sequential 
cascade of phosphorylation reactions that can result, on the one 
hand, in the activation of myosin light chain klnases to initiate 
contraction of the smooth muscle cell or, on the other hand, in the 
activation of MAP (mitogen activation protein) klnases, which can 
stimulate proto-oncogene expression and mitogenesis ofthe same 
smooth muscle cell. Both the G-protein-coupled and the protein 
tyrosine ldnase pathways appear to converge at the MAPK kinase 
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step in the phosphorylation cascade. Therefore, receptor-medi- 
ated contractile and proliferative responses share common signal 
transducing mechanisms. Functional responses of vascular smooth 
muscle cells to vasoactive agonists are representative of "stimulus- 
response coupling" and may broadly define the status of many of 
the common extracellular signals, surface receptor systems, and 
intracellular regulatory mechanisms present. The vascular smooth 
muscle cells involved in intimal hyperplasia re considered to 
change from a "contractile" phenotype to a "synthetic" pheno- 
type to proliferate, and then at later stage, to adopt a more 
contractile phenotype. Irrespective of their age, vein grafts remain 
functional conduits. Retrieved human bypass grafts in place for as 
long as 17 years show markedly altered vasomotor function that is 
attenuated compared to that of the saphenous vein. Endothelial 
cell function (NO or PGI 2 mediated relaxation) is impaired, and 
the vein grafts become more sensitive to aminergic agonists and 
less sensitive to inflammatory and peptidergic agonists. Longterm 
vasomotor changes m vein grafts are of interest as they may be 
used to study phenotypic changes in both endothelial nd smooth 
muscle cells. Changes in receptor-mediated responses provide 
valuable information on the functional aspects of the cell mem- 
brane, and on both transmembrane and intracellular signalling 
pathways. 
With few exceptions, patients who undergo vein bypass graft- 
ing have a significant degree of arteriopathy, and concomitantly 
have one or more atherogenic risk factors present. Hypertension 
in both human and experimental models does not affect the 
development of intimal hyperplasia in the short or long term. 
Furthermore, it appears that hypertension is not associated with 
the later development of vein graft atherosclerosis. In contrast, 
both experimental nd clinical studies have shown an association 
of hyperlipidemia with the development of intimal hyperplasia/ 
atherosclerosis and with higher vein graft failure rates. Clinically, 
diabetes does not appear to impact significantly on vein graft 
patency, but experimentally it does increase short-term intimal 
hyperplasia development. In cases of combined hypertension and 
hyperlipidemia, there appear to be no additive effects on intimal 
hyperplasia development in vein grafts compared to hyperlipid- 
emia alone. In contrast, however, the combined presence of dia- 
betes and hyperlipidemia has a significant additive effects on the 
formation ofintimal hyperplasia n experimental vein grafts. Inter- 
estingly, the profile of vasomotor function of experimental vein 
grafts, in situations where more than one atherogenic risk factor is 
present, is attenuated compared with the comparative situation 
where only one disease state is present, and the observed profiles 
are very similar to those observed in retrieved human vein grafts. 
Therapies to limit the development of intimal hyperplasia in 
vein grafts continues to attract considerable attention; however, 
no effective clinical regimen is presently available to counter the 
intimal hyperplastic response found in vein grafts. Minimizing the 
degree of implantation i jury appears to be a simple and effective 
first step. The use of aspirin is associated with a decrease in early 
thrombotic events in vein grafts but has not been documented to
reduce the incidence of restenosis or the development of athero- 
sclerosis. Various class of compounds used to control intimal 
hyperplasia have shown promise in experimental vein bypass mod- 
els but have not been translated into either clinical trials or clinical 
success. There is a maximal degree of inhibition that can be 
achieved therapeutically, given the premise that vein grafts must 
undergo a degree of "arterialization" as they adapt to the in- 
creased hemodynamic forces placed on them by the arterial circu- 
lation. Finally, one must be cautious in interpreting the results of 
clinical trials that have attempted to pharmacologically reduce the 
development of angioplasty-induced hyperplastic restenosis be- 
cause in many respects vein graft intimal hyperplasia is a distinct 
entity. 
Mark G. Davies, MD, PhD 
Per-Otto Hagen 
Duke University Medical Center 
Durham, N.C. 
CONTROL OF  NEOINT IMAL  HYPERPLAS IA  IN  
PTFE  GRAFTS 
Synthetic vascular grafts are used to bypass obstructions in large or 
high-flow vessels. Their utility is diminished because they are not 
fully incorporated into the surrounding tissue and are therefore 
more susceptible to infection and thrombosis than a biologic 
conduit. When placed into low-flow circuits, particularly as distal 
bypasses, they develop stenosing neointimal lesions at the anasto- 
moses that narrow the lumen, reduce flow, and further increase 
the likelihood of sudden thrombosis. This problem is not limited 
to synthetic bypass grafts; it afflicts other devices (such as stents) 
and is probably aprimitive form of vascular response to injury and 
wound healing designed to generate a transition from the native 
vessel to a rigid prosthesis. 
In t ima l  hyperp las ia  in  baboon PTFE  gra f ts  
To improve our understanding of neointimal hyperplasia, we 
have studied the process in a primate model. Four millimeter- 
diameter expanded PTFE grafts (10 to 90 mm internodal dis- 
tance, supplied by W. L. Gore & Assoc.) are inserted into the 
aortoiliac irculation of baboons.l,2 The lower-porosity grafts heal 
by ingrowth of endothelinm and smooth muscle cells (SMCs) 
across the anastomoses, and the intimal thickening is limited to 
the ends of the grafts. The center of the grafts longer than ca 8 cm 
remains indefinitely without an endothelial surface. The more 
porous grafts (60 and 90 ram) rapidly develop a uniform intimal 
thickening along the graft because of the transmural ingrowth of 
microvessels from the surrounding ramdation tissue as well as the 
tissue ingrowth across the anastomoses from the adjacent cut 
arteries. The microvascniar endothelium and pericytes seem to be 
able to alter their phenotype. The endothelium switches from a 
tubular configuration to a monolayer, while the pericytes express 
smooth muscle proteins and proliferate to form a multilayered 
neointima. 
In the porous (60 mm internodal distance) grafts, the endo- 
thelial ayer is established within 2 weeks. The intimal thickening 
then develops over several months as SMCs and matrix accumu- 
late. It is of interest hat the proliferating SMCs are situated 
underneath and adjacent o the endothelium and not near the 
graft itself, the region containing macrophage-derived multinude- 
ated giant cells. This observation has formed the basis for an 
hypothesis discussed later on for SMC growth control in the 
intima. 
E f fec ts  o f  a l te red  b lood  f low on  in t ima l  
hyperp las ia  
An increase in blood flow usually elicits a vasodilator response. 
Because PTFE grafts are rigid and therefore cannot dilate, the only 
way the graft lumen can be made larger is by inhibition of intimal 
thickening or atrophy of the established intima. We tested this 
hypothesis n baboons by increasing the blood flow and observing 
the pattern of healing after graft placement? -5 In every instance, 
high flow is associated with decreased intimal thickening even 
though the basic organization of the intima is preserved. Further- 
more, if the intima is established under conditions of normal flow 
and then flow is increased by inserting a femoral fistula, the intima 
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regresses by the loss of cells and matrix. If the experiment is
performed the other way round (switch from high to normal flow 
after the initial phase of healing), the intimal area increases by 
fivefold in the course of 1 month! The increase in intimal area is 
due to SMC proliferation ext to the endothelium beginning 4
days after the flow switch. All of these flow-modulated vents take 
place in the absence of endothelial denudation or thrombosis. 
That SMCs seemed to proliferate in the absence of thrombo- 
sis and in the presence of endothelium is puzzling. In balloon- 
injured vessels, SMCs proliferate and migrate only in regions 
lacking endothelium where platelets have attached to the surface 
and degranulated. Depletion of the circulating pool of platelets 
with an antiplatelet antibody or early restoration of the endothe- 
lium either by local regeneration rby deliberate seeding onto the 
denuded surface inhibit inrimal thickening. 6 These seemingly dis- 
parate observations can be reconciled ifwe consider the possibility 
that negative as well as positive factors play a role in the regulation 
of wall mass. The endothelium ight be the source of growth 
inhibitors, although other sources are quite conceivable. In in- 
jured arteries, the pool of growth inhibitors would be depleted 
rapidly with removal of the endothelium. In the PTFE grafts, 
because the endothelium is continuously present, the expression 
of the inhibitor gene or the gene product must be sensitive to 
changes in blood flow; if the hypothesis  correct, the gene would 
be induced by high blood flow and turned off by normal or low 
flow. 
Endothelial nitric oxide synthase (ecNOS) is a good candidate 
inhibitor gene. It is exquisitely sensitive to shear stress and gener- 
ates nitric oxide (NO) from L-arginine. NO inhibits SMC growth 
in vitro and in vivo, and it can under some circumstances cause cell 
death. 7NO is an important physiologic vasorelaxant and therefore 
possesses both growth inhibitor and vasodilator activity. It appears 
that other vasorelaxants are also SMC growth inhibitors (e.g., 
natriuretic peptides), whereas factors that stimulate SMC growth 
can induce vasocontracrion (e.g., PDGF, angiotensin II). 8 
Thus SMC growth and intimal thickening in injured arteries 
and heating PTFE grafts might be regulated by the relative balance 
of growth inhibiting and growth promoting substances. Such a 
scheme might also be operating during vascular development to
control vessel mass as well as luminal area, and we expect it in turn 
to be responding to changes in the hemodynamic forces, blood 
pressure, and flow. In the intima overlying the PTFE grafts and in 
the adjacent lilac arteries, ecNOS is expressed in the luminal 
endothelinm and is downregulated after a switch from high to 
normal flow. At the same time, PDGF-A chain and PDGF recep- 
tor alpha are induced. 9 Whether the changes in these genes are 
required for the induction of SMC replication isnot yet known. 
Conclus ion 
The investigation of mechanisms of intimal thickening and 
SMC growth in injured arteries and synthetic grafts has led us to 
the hypothesis that intimal hyperplasia s regulated by negative as 
well as positive ffectors. A detailed understanding of this process 
should provide the basis for the development of physical and 
pharmacologic strategies to inhibit inrimal hyperplasia nd graft 
failure. 
Alexander W. Clowes, MD 
University of Washington School of Medicine 
Seattle, Wash. 
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ANGIOGENIC  MECHANISMS IN HEAL ING OF 
SYNTHETIC  GRAFTS 
An estimated 550,000 vascular grafts are implanted annually in the 
United States, but patency rates for bypasses of medium caliber 
vessels such as femoropopliteal and femorotibial bypass proce- 
dures range only from 15% to 30% after 5 years. Optimization of 
endothelial cell (EC) ingrowth and function onto vascular grafts 
with a concomitant control of SMC proliferation would likely 
improve these outcomes and lead to the use of grafts in recon- 
structions of the venous ystem and smaller caliber arteries, as well 
as their use for drug and gene product delivery into the circula- 
tion. The impregnation ofvascular grafts with therapeutic agents 
contained within a controlled elivery vehicle and in a biologically 
active configuration can theoretically be of clinical value for either 
local drug delivery for modifying the response of blood or the 
surrounding tissue to the implanted graft or for intraarterial or 
intravenous drug delivery for systemic applications. Self-limited 
conditions that require a definable and temporary period of drug 
delivery are likely the optimal initial clinical targets. 
Theoretical strategies for achieving endothelialization of
blood-contacting surfaces within prosthetic grafts include both 
the direct application of ECs and the development of systems 
designed to induce spontaneous endothelialization. EC seeding of 
synthetic vascular grafts has been extensively investigated. In clin- 
ical trials to date, however, the benefits have been modest largely 
due both to the highly abnormal surface onto which the cells are 
seeded and to the manipulation of the cells. The alternate strategy 
of stimulating spontaneous endothelialization viaangiogenesis has 
been the predominant approach taken by our laboratory. Endo- 
thelial cells could potentially be recruited either from migration 
and proliferation of arterial ECs across the anastomosis or via an 
angiogenic response directing capillary infiltration across the graft 
wall from the surrounding tissue bed. Rat carotid artery balloon 
deendothelializarion studies have suggested a limited capacity for 
spontaneous resurfacing of large denuded areas from the adjacent 
uninjured arterial segments. Lindner reported that this cessation 
of reendothelializarion c uld be partially overcome by intravenous 
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administration f "high" levels of FGF-2 (121 p~g/day) 1 but at 
the expense of a significant increase in medial SMC proliferation. 2 
The surface area of a clinically relevant vascular graft is much 
greater, suggesting that this approach may not be practical for 
prosthetic bypass grafts. 
Pepper and Montesano have shown that microvascular ECs 
plated on the surface of three- dimensional collagen or fibrin gels 
can be induced to reorganize into invading branching and anasto- 
mosing capillary networks by the introduction of FGF-2 into the 
gels, an effect mediated in part through local lysis of the underly- 
ing matrix, s This group further showed a significant increase in in 
vitro angiogenesis when VEGF was added to the FGF-2.4 
Our laboratory has impregnated vascular grafts primarily with 
FGF- 1 (acidic FGF) to induce endothelialization, a d with hepa- 
rin, antisense oligonucleotides and mitotoxins to inhibit SMC 
proliferation. These techniques, with modifications, may achieve 
similar esults when applied to other vascular interventions such as 
angioplasty and en~:arterectomy. 
The ability ofa varieq¢ of FGF delivery systems to promote the 
in vitro growth of ECs was studied in cell culture. We developed 
our current method in which FGF-1 and heparin are introduced 
into suspension within a fibrinogen/thrombin (fibrin glue [FG]) 
matrix, sWith this system we have seen a dose dependent capability 
of FGF-1 with heparin in FG to support the growth of both canine 
and human ECs. 
We performed a series of in vivo experiments o evaluate the 
bioactivity of this preparation for vascular graft healing. 6 In vivo 
release kinetics from 60 wIND ePTFE grafts were quantitated 
using FG suspensions containing human 125I-rFGF-1, 10 ng/ml; 
heparin, 33 or 200 U/ml;  and fibrinogen, 32 mg/ml, polymer- 
ized with human or bovine thrombin, 0.32 U/ml.  Release kinetics 
were such that after 7 days in circulation 13.4% + 6.9% (using 33 
U /ml  heparin) and 5.4% + 0.2% (using 200 U/ml  heparin) of the 
applied 12SI-FGF-1 remained on the prosthesis (4% and 3% after 
30 days). The initial relatively rapid release of FGF-1 into circula- 
tion in vivo is likely a function of diffusion and shear stress. The 
later slow persistent release is likely at least in part a function of 
endogenous fibtlnolytic activity resulting in fibrin degradation and 
FGF-1 release. Sheep ECs transduced with the cDNA encoding 
for t-PA and overexpressing t-PA protein (kindly provided by Dr. 
David Dichek) were seeded onto fibrin glue treated surfaces under 
static culture conditions. Within 3 to 5 days, FG directly beneath 
these sparsely plated cells was totally digested, leaving FG only in 
areas not directly supporting adherent cells. 
The in vitro and canine in vivo thrombogenicity of FG applied 
to ePTFE was quantitated using 1rain platelet deposition studies. 
After 60 and 120 minutes ofperfusion (both in vitro and in vivo) 
significantly less platelet adherence was found on the treated 
ePTFE compared either with untreated or with preclotted ePTFE. 
We next evaluated the effect 0f this FG/hep/FGF-1 prepara- 
tion on graft healing with attention to endothelialization a d EC 
proliferation in canine aortoiliac implants, ePTFE grafts treated 
with FG/hep/FGF-1 were implanted contralateral to either of 
two negative control groups, either ePTFE grafts treated with only 
FG/hep or untreated ePTFE grafts. At 28 days every FG/hep/  
FGF-1 graft revealed a totally endothelialized surface and exten- 
sive transmural capillary infiltration through the interstices of the 
graft wall, a pattern never found in any specimen from either 
control group. En face autoradiography revealed a significant 
increase in EC mitotic activity in the 28-day explants pretreated 
with FG/hep/FGF-1 (p < 0.05). 
We then studied the effect of this FG/hep/FGF-1 pretreat- 
ment on 30 cm long ePTFE grafts. 6 Thoracoabdominal aortic 
implants (three groups as above) were implanted into dogs and 
explanted after 10, 30, or 140 days. Histologically, the untreated 
grafts were lined solely with thrombus through 30 days. By 20 
weeks small islands of pseudointima containing several layers of 
SMCs covered portions of the graft interspersed with areas of 
thrombus. The FG/hep-treated specimens at 30 days and at 20 
weeks displayed similar islands ofpseudointima with large areas of 
residual fibrin coagulum remaining. The FG/hep/FGF-1 treated 
grafts at 10 days showed a much more extensive mesenchymal 
tissue ingrowth into the body of the graft with SMCs and capillar- 
ies present in the outer 80% of the wall. By 30 days the entire graft 
wall was extensively capillarized and the inner capsule displayed 
near 100% confluence of a factor VIII-positive cell layer over 
abundant SMCs and collagen. At 20 weeks the interstitial capillar- 
ization remained and a complete neointima (139 ixm thick, signif- 
icantly greater than controls) was present in every FG/hep/  
FGF-1 explant. Cross-sectional utoradiography showed at 30 
days a proliferative response to FGF-1 of 9.6 + 4.4% (in 10 
hours). At 20 weeks the mitotic indices had decreased, measuring 
less than 1% with no difference among the groups. 
The use of this preparation i small-diameter a terial bypass 
procedures requires that neointimal thickening be minimized. 
Although heparin synergizes with FGF-1 in stimulating SMC 
proliferation, by itself heparin can inhibit SMC proliferation. We 
quantitated SMC and EC proliferative responses in vitro to vary- 
ing ratios of FGF-I: heparin delivered either in soluble form or 
within FG suspensions onto which cells were seeded7 Primary 
canine carotid artery and rabbit aortic SMCs, both made quiescent 
in serum free media, showed no proliferative response to soluble 
FGF-1 in the absence ofheparin. The addition of 5 or 50 U/ml  
heparin induced asignificant and FGF-1 dose-related proliferative 
response. The addition of 500 U/ml  heparin completely abol- 
ished all SMC proliferation in response to even 100 ng/ml of 
FGF-1. When FGF-1 and heparin were supplied from FG suspen- 
sions, with no soluble FGF-1 or heparin added to the media, a 
similar pattern persisted. Proliferation was significantly increased 
on fibrin glue with FGF-1 and containing 5 or 50 U/ml  heparin 
(p < 0.0001 for both) but significantly inhibited on fibrin glue 
with FGF-1 plus 500 U/ml  heparin (p = 0.014 vs negative 
control without FGF-1 or heparin). Concomitant studies using 
human umbilical vein ECs showed a small but significant stimula- 
tion of proliferation by FGF-1 in the absence of heparin, but 
significant progressive increases in proliferation in response to 
progressively increased heparin concentrations, including 500 
U/ni l ,  within the FG suspensions. Thus a relative concentration 
of 500 U heparin:10 ng FGF-1 selectively stimulates endothelial 
cell growth in vitro. 
We treated ePTFE with FG containing FGF-1, and this 
higher heparin concentration a d implanted these as canine tho- 
racoabdominat aortic grafts. Results again demonstrated anFGF- 
1-induced stimulation of capillary rich tissue ingrowth across the 
graft wall and surface endothelialization. However neointimal 
thickening was not diminished as compared with the previous 
study using lower concentrations of heparin. 
Similar FG surface application can be used in arterial injury 
models ofendarterectomy. Twenty adult dogs underwent bilateral 
balloon injury to a 6 cm segment of their carotid arteries, which 
resulted in a reproducible r moval of the intima and 4 to 6 medial 
lamellae. In 10 group I animals, FG containing FGF- 1 (11 ng/ml) 
and heparin (250 U/ml)  was applied to the luminal surface of one 
of the two balloon-injured carotid arteries. In l0 group II animals, 
an identical FG preparation with FGF-1 and heparin was applied 
to the surface of one carotid artery, while the contralateral carotid 
received FG/FGF-1/heparin that also contained autologous ECs 
(P3, 5 to 10 X 104 cells/cm2). Five animals from both group I 
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and group II were killed at 10 days and the remaining 10 animals 
at 30 days. There was no measurable neointimal formation at 10 
days. There was no difference in neointimal measurements be- 
tween the treatments in group 1 30-day dogs. There was a signifi- 
cant decrease at 30 days in neointimal maximal thickness and area, 
intima/media thickness ratio, and intima area/media area ratio in 
group II arteries that were treated with FG/FGF-1/heparin plus 
EC along with a near-significant decrease (p = 0.06) at 10 days in 
medial SMC proliferation in this same group. We assessed the 
effect of this surface modification on H~In platelet deposition in 
vivo and found a 45.2% decrease (p = 0.008) on the treated side 
after 120 minutes, with a trend toward decreased thrombogenicity 
persisting after 30 days. 
Currently in progress are related studies using FG to delver 
chimeric and mutant species based on FGF with structural and 
biologic properties designed to selectively maintain the EC prolif- 
erative response but without concomitant SMC mitogenicity. 
Howard 1). Greisler, MD 
Loyola University Medical Center and Hines VA Hospital 
Maywood, Ill. 
Supported in part by a grant from the National Institutes of 
Health, grant ROIHL 41272 
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VASCULAR RECONSTRUCTION: TO 
REBUILD OR BUILD ANEW 
ANGIOGENESIS  AND VASCULAR REPAIR 
AFTER IN JURY 
Virtually all forms of arterial reconstruction result in substantial 
injury to treated vessel segments, and the subsequent healing 
response often leads to recurrent lumen narrowing. Although 
much has been learned of the cellular and molecular basis of the 
response to injury, remarkably, no therapy to prevent restenosis 
has been forthcoming. Restenosis has been attributed to smooth 
muscle cell (SMC) proliferation at the site of injury, leading to 
new tissue growth that encroaches the artery lumen. This hypoth- 
esis prompted the search for a treatment to prevent SMC replica- 
tion at sites of vascular reconstruction. A multitude of drugs have 
been identified that effectively inhibit SMC growth and migration 
in culture and prevent intimal hyperplasia in animal models of 
arterial injury, but not one of these agents has consistently 
inhibited restenosis n human beings. In fact, so many strategies 
have failed that common paradigms of restenosis are being 
challenged by new hypotheses, i Disparate results may be due to 
species differences in the regulation of SMC growth 2 or to 
oversimplifying the injury response in models that lack complex 
atherosclerosis. 3 Alternatively, the intimal hyperplasia hypothe- 
sis equating lumen narrowing with intimal growth may simply 
be wrong} ,3,4 This review will briefly discuss the concept of 
remodeling in atherosclerosis and restenosis and introduce a 
unique nonhuman primate model that may help to better 
define the response to injury in arteries with preexisting com- 
plex atherosclerosis. 3 
Is proliferation important in restenosis? 
For obvious reasons, cell proliferation has not been assessed in 
clinical restenosis trials, so we do not know whether drugs have 
failed to inhibit replication after injury. In 1993 a controversy was 
introduced by O'Brien et al., who published an analysis of prolif- 
eration (PCNA labeling) in 200 human coronary atherectomy 
specimens after angioplasty, r They concluded that proliferation 
was quite low after angioplasty and that SMC replication may be 
unimportant in restenosis. While these results have been chal- 
lenged in similar studies,  the controversy persists. As attention has 
shifted away from cell proliferation changes in wall geometry or 
"remodeling" have become the focus of many studies. 
(Re)stenosis as a failure of  remodeling 
Few terms have been used as imprecisely as "remodeling" to 
describe changes in artery wall structure after injury. The concept 
of vascular remodeling comes from physiologists and developmen- 
talists who have used the term to describe adaptive changes in 
artery wall structure in response to altered hemodynamic forces. 
As an organism grows tissues require more blood flow and arteries 
will enlarge to accommodate his need. Lumen caliber and wall 
thickness increase to maintain shear stress and wall tension within 
a physiologic range. These responses are central to the homeosta- 
sis of vascular circuitry and the wide range of environments o
which arteries can adapt is remarkable. As arteries age and develop 
atherosclerosis imilar remodeling occurs, s,6 The artery wall en- 
larges to accommodate inrimal thickening and thereby preserves 
lumen caliber and end-organ blood flow. Remodeling is a normal 
physiologic process by which arteries maintain optimal geometry. 
Stenosis develops only when remodeling fails. This same mecha- 
nism has been proposed in restenosis where lumen narrowing may 
represent a failure of the remodeling process to accommodate 
intimal thickening and maintain lumen caliber. 1,4 
Clues f rom a nonhuman pr imate  mode l  o f  
atherosclerosis 
The most extensively characterized nonhuman primate model 
ofatherosclerosis is the cholesterol-fed cynomolgus monkey (Ma- 
caca fascicularis). 6,9 Within months of eating an atherogenic diet 
(e.g., 0.2 mg cholesterol/Cal), fatty streaks and intimal esions 
begin to develop in a pattern typical of early human atherogenesis. 
Branch points and ostia are affected first, and after 2 to 3 years 
advanced lesions develop with complicating features typical of 
human plaques. Leukocyte infiltration, calcification, eovascular- 
ization, intraplaque hemorrhage, and necrosis occur as lesions 
progress. As in human beings, monkey arteries usually remodel in 
response to atherosclerosis, enlarging to accommodate plaque 
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growth and thereby maintain lumen caliber. 6However, stenoses 
do occur and occasionally precipitate myocardial infarction, 
stroke, visceral ischemia, or limb loss. As in human beings, lipid 
levels (TPC, HDL, LDL and Lp[a]) correlate with lesion progres- 
sion and extent. 6,9 This model presents a unique oppornmity to 
study the injury response in a species closely related to human 
beings with similar plaque morphology and lipid and coagulation 
profiles. 
Angioplasty increases lumen caliber in this model by fractur- 
ing preexisting plaques and by stretching or tearing the overlying 
media and advenritia. 3 Medial necrosis with loss of SMCs is com- 
mon near sites of plaque disruption. Monkey lesions are rich in 
tissue factor, and a thin mural thrombus deposits at fracture sites 
despite heparinization. Acute thrombosis is unusual, however, 
occurring in less than 3% of more than 200 angioplasties per- 
formed to date. Proliferation begins within 2 days and is signifi- 
cant in all wall layers (adventitia, media, and atheroma). Prolifera- 
tion peaks at 4 days and returns to baseline between 7 and 14 days 
after angioplasty. New tissue begins to form late in the first week as 
cells move into the damaged wall and into mural thrombus coat- 
ing fractures and dissections. This tissue rapidly fills defects, and 
the intima thickens dramatically between 14 and 28 days as cells 
migrate toward the lumen and elaborate xtracellular matrix. The 
early neointima ishistologically distinct from the underlying artery 
wall, having an appearance typical of the loose cellular tissue often 
retrieved by atherectomy from human restenosis. Despite signifi- 
cant accumulation of new wall mass during the first month after 
angioplasty, significant loss of lumen caliber occurs in only one 
half of injured arteries.3 
At first glance, the high proliferation seen during the first 
week after angioplasty in atherosclerotic monkeys appears at odds 
with the low proliferation reported ha human atherectomy speci- 
mens, as mentioned above. 7Beyond the first week of angioplasty, 
however, our data are similar to those of O'Brien et al. It may be 
that too few human specimens were retrieved within the first week 
after angioplasty o accurately detect abrief but significant wave of 
proliferation. Of the four specimens retrieved by O'Brien within 6 
days of injury, three had PCNA-labeled nuclei. Also to be consid- 
ered is that lesions that require reintervention for "restenosis" at 
such an early interval after angioplasty likely differ from those that 
develop restenosis after a successful procedure. Our findings in the 
monkey model suggest hat intimal hyperplasia s a normal and 
consistent component of the injury response in atherosclerotic 
arteries? That is not to say that restenosis results from SMC 
proliferation. To the contrary, our findings suggest hat lumen 
narrowing has little to do with proliferation and new intimal mass 
per se. 
The monkey model provides upport for the concept ofreste- 
nosis as a failure of remodeling. At 28 days after angioplasty, 
intimal area and plaque burden were no different between arteries 
that maintained lumen dilation and those that renarrowed. Injury 
severity scores based on the depth of wall injury were also similar 
in these two groups. On the other hand, artery size (external 
elastic lamina area) was significantly smaller in arteries that lost 
lumen caliber after angioplasty, suggesting that changes in wall 
size determine lumen size? Angioplasty may be successful despite 
intimal hyperplasia if remodeling occurs to accommodate new 
intimal mass. 3,4 
Wound hea l ing :  a tmi fy ing  hypothes is?  
If the quantity of new tissue accumulating atthe site of injury 
does not predict lumen narrowing and restenosis represents a 
failure of remodeling, what factors might be important in prevent- 
ing accommodation? Vessels may fail to remodel and become 
stenotic as a result of the same kinds of tissue contraction seen 
during wound healing. Contraction of wound tissue involves an 
interplay among contractile cells, integtins, and matrix molecules. 
A similar process may occur within injuries caused by angioplasty. 
In cutaneous wounds granulation tissue forms within a provisional 
matrix provided by the wound coagulum. Fibroblasts migrate into 
fibrin-rich clot, proliferate, and begin to produce extracellular 
matrix. These cells differentiate into myofibroblasts, which express 
alpha-actin and contract the granulation tissue to reduce wound 
size. Integtin-matrix coupling provides for cell adhesion, mech- 
anotransduction, a d cytoskeletal reorganization required for rep- 
lication, migration, and contraction. In angioplasty, fracture and 
denudation of the artery wall exposes tissue factor and other 
thrombogenic plaque components o flowing blood. The result- 
ing mural thrombus provides aprovisional matrix analogous to the 
clot within cutaneous wounds. SMCs, inflammatory cells, and 
probably myofibroblasts migrate into the thrombus and begin to 
form a neointima nalogous to granulation tissue. Depending on 
the pattern of extracellular matrix and integtin expression within 
the neointima nd injured wall substantial tissue contraction may 
occur. Such contraction could impair or prevent remodeling and 
accommodation a d lead to restenosis. 
As cutaneous wounds heal, an ordered sequence of matrix 
expression occurs. A similar pattern may occur in healing arteries. 
In the atherosclerotic monkey model, by 7 days after angioplasty 
SMCs in the early neointima begin to express matrix rich in 
hyaluronic acid. This provides a loose hydrophilic onnective tis- 
sue that may facilitate cell movement and proliferation. Hyaluro- 
nan, common in fetal tissues and healing wounds, is modified by 
binding of proteoglycan side-chains. Expression of versican pro- 
teoglycans increases ignificantly by 7 to 14 days and remains 
elevated at 28 days. Type-I procollagen expression begins in the 
adventitia within days of angioplasty. Procollagen-I is expressed 
throughout the neointima t 14 days and then nearest the lumen 
at 1 month. The early neointima is also rich in yon Willebrand 
Factor (vWF), fibrin(ogen) and other plasma proteins. Within 4 
months of injury a clear evolution in neointimal composition 
becomes evident. While hyaluronan is present, versican is not 
expressed at 4 months and staining for vWF and other plasma 
proteins is less intense. Procollagen-I expression continues in the 
adventitia, and the luminal aspect of the neointima nd elastin 
fibers not seen at 1 month are present hroughout the 4-month 
neointima. The neointima becomes histologically less distinct 
from the underlying plaque at 4 months than at ] month. 
The magnitude and timing of expression of specific integrins 
by smooth muscle cells could contribute significantly to the con- 
traction of extracellular matrix components within the artery wall. 
The recent EPIC trial has focused attention on the beta-3 inte- 
grins as an antibody Fab fragment (c7E3) directed against he 
human platelet IIblIIa receptor was shown to significantly reduce 
adverse outcomes after angioplasty (death, MI, and repeat revas- 
cularizations). 1° The effect is durable with follow-up now out to 3 
years, but the mechanism underlying these benefits remains un- 
clear. Whether c7E3 inhibited restenosis  also unknown because 
follow-up angiography has not been reported. We and others have 
speculated that c7E3 might be acting in part by blocking SMC 
aVb3 integrins, aVb3 is important for SMC and fibroblast attach- 
ment to fibrin(ogen), vitronectin, vWF, and denatured collagen. 
Contraction of fibrin gels by cultured SMCs can be prevented by a 
blocking antibody against aVb3, and this antibody also inhibits 
angiogenesis in vitro and in vivo. Little aVb3 is present in normal 
human arteries but expression i creases in atherosclerosis. ~l Ex- 
pression within the artery wall after angioplasty has not been well 
defined. In the monkey model aVb3 expression i creases substan- 
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tially by 7 days after angioplasty and is prominent in the neointima 
at 28 days. Further experiments are underway to more carefully 
define the timing of expression and cell-types expressing aVb3 
after injury. Whether blocking aVb3 and other SMC integrins will 
promote remodeling by inhibiting extracellular matrix contraction 
and reorganization i  injured atherosclerotic arteries remains un- 
clear. 
Randolph L. Geary, MD 
Bowman Gray School of Medicine, Wake Forest University 
Winston-Salem, N. C. 
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MAKING HEMODIALYSIS  GRAFTS WORK 
Although autogenous arteriovenous fi tulas are preferred for dial- 
ysis access, most patients will require a prosthetic bridge fistula at 
some point due to lack of suitable vein. Most available types of 
arterial substitute have been used for this purpose, including 
saphenous vein, Dacron, polytetrafluoroethylene (PTFE), umbili- 
cal grafts, and bovine heterografts. Biologic grafts have fallen out 
of favor because they tend to dissolve with infection, are prone to 
aneurysm formation, and are difficult to revise when they throm- 
bose. Saphenous vein is still used occasionally, particularly in 
patients who have had problems with infection, but patency is not 
as good as that of Dacron or PTFE. Dacron has fallen out of favor, 
possibly due to difficulty puncturing this material. PTFE is now 
the most commonly used prosthetic graft, and is widely accepted 
because it is flexible, porous, easy to handle, puncture, and revise, 
and may resist infection better than Dacron. The most common 
configuration is a 6 mm tube graft with standard, 10 to 30 I~m 
interuodal distance porosity. 
Sixty percent of PTFE grafts fail yearly, usually due to stenosis 
at the venous end. 1,2 A similar process occurs in arterial grafts, but 
the lesion is not as virulent. It is perplexing that this hyperplastic 
response is so robust in these high-flow fistulas because we have 
found increased flow to inhibit intimal hyperplasia n PTFE grafts 
placed in the arterial circulation 3 and after vascular injury. ~ Unique 
features of artetiovenous grafts include extremely high flow rates, 
turbulence causing vessel wall vibration, repeated graft puncture, 
infusion of processed blood, distal anastomosis to the thin-walled 
vein rather than an artery, and alterations in plasma components 
caused by uremia. Mso, the venous end of the graft may be bathed 
in mitogens released uring passage of the blood through the 
dialysis tubing or during activation ofplatelets at the site of needle 
puncture. 
Examination of stenotic lesions from human specimens sug- 
gest that proliferation of vascular smooth muscle cells (VSMC) is 
an important component of stenosis at the venous anastomosis. 
Rekhter and coworkers s described the histology of stenosing le- 
sions at the venous anastomosis of seven human PTFE access 
grafts. Lesions consisted primarily ofVSMC (~-actin positive), but 
macrophages and lymphocytes were also present, particularly in 
association with microvessels. High rates of cell proliferation (pos- 
itivity for proliferating cell nuclear antigen) were found in cells in 
VSMCs and endothelial cells in the microvessels and in macro- 
phages. Cell proliferation and angiogenesis may result from para- 
crine and autocrine ffects of mitogens made by these cells. M- 
though in a previous report his group did not find hemosiderin 
the stenotic vein distal to the anastomosis, 6 in this study hemosid- 
erin was found in the media and adventitia of most specimens. 
Because hemosiderin is a marker for previous thrombosis, this 
finding suggests that thrombosis could be a feature of lesion 
formation. 
We have developed an animal model of access failure. 7 We 
chose sheep because their coagulation system is similar to that of 
humans. Also, a uremic sheep model was used for the develop- 
ment of erythropoietin therapy and could be used to study the 
effects of uremia on graft function. The location of carotid-to- 
jugular vein grafts in the neck of these animals allows the use of 
grafts that are the same size as those used clinically and also 
provides easy access for graft puncture to simulate dialysis. 
The arterial end of these experimental grafts have minimal 
ingrowth of tissue from the adjacent vessel, no narrowing of the 
lumen, and no thrombosis. In contrast, the venous ends develop 
lesions that significantly narrow the lumen. Thrombus is a promi- 
nent feature and often extends for several centimeters from the 
venous anastomosis. The stenosing lesions are composed mainly 
of VSMCs, but also have areas of marked neovascularity. Throm- 
bus is actively organized by invasion of macrophages and capillar- 
ies from adjacent areas ofneointima. In some areas, the thrombus 
is covered by endothelium, but endothelial coverage is not com- 
plete. 
We postulate that active injury to the neointima t the venous 
anastomosis with thrombosis  an important component of lesion 
formation in this model. This may be caused by abnormal flow 
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patterns at the venous end of the graft that promote thrombosis as 
well as instability of the endothellum. Perhaps the high fistula flow 
causes detachment of the advancing endothelial edge that grows 
in from the adjacent vein. Thrombin and other activated coagula- 
tion factors may act as mitogens and chemoattractants for VSMCs. 
Activated macrophages that are mobilized to resolve the thrombus 
also may produce factors that contribute to lesion growth. The 
importance of thrombosis has been recognized in restenosis after 
angioplasty. Libby and coworkers s have suggested that local 
thrombus along with vessel injury act as instigators of autocrine 
and paracrine growth factor and cytokine expression by VSMCs 
and leukocytes. These secondary effects become self-sustaining 
and produce restenosis that occurs many months after injury, as 
opposed to experimental models of injury where hyperplasia de- 
velops within weeks. If a similar process contributes to access 
failure in humans, then graft function may be improved by provid- 
ing a more stable endothelinm, limiting thrombosis, uppressing 
VSMC growth, or even inhibiting the ingrowth of endothelium 
from the adjacent vessel by modifying the graft surface at the 
venous end. 
If thrombosis and thrombus organization are important to 
lesion formation, then anticoagulation r antiplatelet agents could 
improve patency. Aspirin therapy was found to improve the pa- 
tency ofScribner shtmts used in the early days of dialysis, but there 
are no large studies of the effect of this type of therapy on dialysis 
grafts. Many patients take aspirin for their associated cardiovascu- 
lar disease, and there is a reluctance to use anricoagulation medi- 
cation, which may cause troublesome bleeding after graft punc- 
ture for dialysis. Perhaps newer anriplatelet or antithrombotic 
agents or localized forms of therapy could reduce stenosis. There is 
some experimental evidence that carbon coating of the graft surface 
can decrease thrombogenicity due to the increased negative surface 
charge. Convincing clinical data for these grafts is lacking. 
Turbulent flow at the venous anastomosis may contribute to 
lesion formation by damaging the endothelium and perhaps even 
disturbing the deeper structures of the vessel wall. In a canine 
model, vein wall thickening at the toe of the anastomosis was 
reduced in tapered, 4- to 7-ram PTFE grafts when compared to 
standard, 6 mm grafts.9 Wall thickness correlated with the amount 
of vibration in surrounding tissue noted on color duplex scanning, 
suggesting that kinetic energy transfer to the vein stimulates wall 
thickening. In our sheep model, creating aflared cuffat he venous 
end of the graft reduces the thickness of the neointima t the 
anastomosis. However, lesion thickening still occurs at the transi- 
tion point between the normal graft and the widened section, 
suggesting that flow patterns in this transition zone may promote 
thrombosis and lesion formation. 
If continued breakdown of the neointima incites recurrent 
thrombosis and contributes to intimal hyperplasia, then it may be 
helpful to stabilize the endothelium by using more porous PTFE. 
Increasing the interuodal distance from the standard 10 to 30 I~m 
to 60 txm produces a surface that is initially more thrombogenic 
but allows ingrowth of capillaries to the luminal surface along the 
entire length of the graft. In animal models, this results in a 
confluent endothelial lining within 2 weeks. VSMCs migrate in 
under this endothelial layer and proliferate to form a neoinrima of 
tmiform thickness, without increased narrowing at the anastomo- 
ses. These cells respond to increased flow caused by a distal 
arteriovenous fi tula, with upregulation of nitric oxide synthase 
and reduced neointimal thickening. 3,1° It is possible that this 
endothelial lining would be more stable than the endothelium that 
grows onto the surface of a conventional graft, and therefore would 
result in less thrombosis and intimal proliferation ha access grafts. 
We have successfully seeded these more porous PTFE grafts 
with VSMCs transduced with the erythropoietin gene. The in- 
creased porosity allows cells to occupy the matrix of the graft as 
well as residing on the luminal surface. Our goal is to produce an 
access graft that can deriver erythropoietin therapy for the anemia 
associated with chronic renal failure. If successful, this technique 
could also be used to deliver other gene products that could limit 
thrombosis and cellular proliferation to improve graft function. 
Grafts are now being manufactured with a variable internodal 
distance that changes from the inner to the outer surface of the 
wall. The potential benefit of increased outer porosity is improved 
incorporation of the graft due to better tissue ingrowth. If the 
inner portion of the graft has conventional internodal distance 
then preclotting isnot necessary because blood will not penetrate 
this barrier. However, endothelialization by capillary ingrowth will 
also be inhibited. Because the flow surface is not affected by this 
modification, graft function is not likely to be enhanced. Another 
recent design modification is surrounding the graft with PTI:E 
fibers and an outer wrap to create a mechanical seal after graft 
puncture, allowing immediate use of the graft for dialysis. A 
preliminary report with this device was somewhat encouraging 
(there was a high failure rate in the learning period but early 
cannulation was achieved). The effects of this modification on 
long-term incorporation and patency have not been reported, and 
reoperation on the wrapped segment could be cumbersome. 
Although our sheep develop marked ialysis graft stenosis in 
the absence of uremia, systemic factors may play an important role 
in patients with chronic renal failure. Serum from patients with 
chronic renal failure contains factors that stimulate proliferation of 
VSMCs in vitro. In a recent study of 30 nondiabetic hemodialysis 
patients with autogenous access fistulas, graft stenosis was associ- 
ated with increased serum levels of monocyte chemoattractant 
protein-1 and interleukin-6 and with hyperinsulinemia, hyperlip- 
idemia, and increased plasma levels of plasminogen activator in- 
hibitor type 1 and factor VII? 1 Lipid and apolipoprotein abnor- 
malities were also associated with fistula dysfunction. These factors 
have been implicated in development of atherosclerotic lesions 
and may enhance the development of stenotic lesions in access 
grafts. If so, drug therapy designed to counteract their effects 
could improve graft function. 
Drug therapy to inhibit cell growth could improve graft 
function. Many agents have been found to limit VSMC prolifera- 
tion in animal models of arterial injury, but none have been 
successful in reducing stenosis in arterial grafts. Several antiprolif- 
erative and antithrombotic drugs as well as local treatments ( uch 
as catheter-delivered a iation and infusion of agents into the wall 
using leaky balloons) are under evaluation for prevention of reste- 
nosis. These could also improve patency of dialysis access grafts. 
In summary, dialysis access grafts are plagued by an unaccept- 
ably high failure rate, mostly due to stenosis at the venous end of 
the graft. This occurs at a much higher rate than in standard 
peripheral bypass grafts and could be due to increased flow, altered 
flow conditions at the venous anastomosis, vibratory energy im- 
parted to the adjacent vein, disruption of the growing edge of 
endothelium from the vein, and thrombus formation on the in- 
jured surface. Thrombosis generates factors that stimulate the 
growth of neointima nd provides a scaffold for ingrowth of 
VSMCs. Our sheep model suggests the importance of thrombosis 
and ongoing injury. Some of the possible methods to improve 
function that are under investigation i clude changing raft ge- 
ometry to improve flow characteristics, modifying the surface to 
reduce tissue ingrowth and thrombosis, seeding the graft with 
generically modified cells that can produce antithrombotic or 
antiprollferative factors, modifying the graft wall to allow in- 
growth of capillaries that can provide an endotheliafized surface, 
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and local or systemic treatment with radiation or drugs to limit 
cellular growth. 
Ted R. Kohler, MD 
University of Washington School of Medicine and VA Puget Sound 
Health Care System 
Seattle, Wash. 
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CONTROL OF THROMBOSIS  ON SYNTHETIC  
GRAFT SURFACES- -GENE TRANSFER APPROACH 
Prosthetic vascular devices are subject o thrombotic omplica- 
tions. 1 A theoretical solution to the problem of prosthetic graft 
thrombosis i the establishment of a relatively nonthrombogenic 
lining along the graft surface by means of endothelial "seeding" or 
"sodding." The first description of this approach was published 
nearly 20 years ago2; however, two decades of work in this area 
have not yet led to major improvements in clinical outcomes. The 
failure of graft seeding to fulfill early expectations has provoked 
comments as to whether graft seeding will ever enter routine 
clinical practice. 3,4 Coincident with the development of this pessi- 
mism, the potential for graft seeding to improve patency rates was 
revived by the demonstration that endothelial cells could be ge- 
netically engineered before being placed on the surface of a vascu- 
lar graft. 3 This demonstration suggested to us e and to others 7,8 
that endothelial cells might be genetically engineered to secrete 
antithromboric proteins before graft seeding. Theoretically, these 
fibtinolytically "enhanced" cells would render the graft surface less 
thrombogenic, leading to prolonged graft patency. Confinement 
of this enhanced fibrinolytic effect to the graft surface might 
obviate the need for systemic antithromboric therapy, with its 
attendant complications. 
In initial in vitro studies, we demonstrated that endothelial 
cells could be genetically modified with retroviral vectors to se- 
crete high levels of tissue plasminogen activator (t-PA). 6 Recom- 
binant -PA produced by the engineered cells was enzymatically 
active and was secreted at stable levels in vitro for several weeks. In 
experiments performed in static in vitro culture (without exposure 
to flow), we detected no effect of t-PA overexpression impor- 
tant components of the  endothelial cell phenotype. Specifically, 
endothelial cells expressing high levels of t-PA had normal rates of 
proliferation, attachment, and migration? Transduced cells ap- 
peared to differ from untransduced or control-transduced cells 
only in their fibrinolytic activity. 
Before the initiation of in vivo studies to test the antithrom- 
boric potency of these t-PA-transduced cells, we considered the 
potential problem that secreted t-PA might be lost rapidly from 
the graft surface. Perhaps a more optimal fibrinolytic molecule 
would be one that was attached to the luminal surface of trans- 
duced cells, decreasing surface thrombogenicity while remaining 
highly concentrated along the length of the graft. To achieve this 
goal, we turned our attention from t-PA to urokinase plasminogen 
activator (u-PA). Unlike t-PA, u-PA is secreted as a single-chain 
proenzyme that is not bound or inhibited by plasminogen activa- 
tor inhibitor type 1, the major physiologic inhibitor of plasmino- 
gen activation. Thus single-chain u-PA might be attached to the 
cell surface in a form that retained potential fibrinolytic activity. 
To accomplish this goal, we modified the u-PA gene to include a 
sequence that causes the u-PA protein to be anchored to the apical 
(i.e., luminal) cell surface.l° This sequence Was successful in direct- 
ing expression of u-PA to the apical cell surface. The cell surface- 
anchored form of single-chain u-PA could be converted to the 
active two-chain form, with a normal specific activity on conver- 
sion. Cells transduced with this modified u-PA gene had increased 
cell surface fibtinolytic activity. Moreover, as a result of the specific 
genetic sequence used to anchor the u-PA protein, some of the 
anchored n-PA was released from the cell surface, again in a fully 
activatable form. Thus endothelial cells transduced with this mod- 
ified urokinase gene had increased fibrinolyric activity, both along 
their apical surfaces and in the surrounding medium. 
Preclinical studies on enhanced fibrinolysis are most optimally 
performed in nonhuman primates. As a prelude to in vivo studies 
in a primate thrombosis model, we tested the fibrinolytic activity 
of baboon cells transduced with vectors expressing either wild type 
or mutant plasminogen activators, l~ The mutant plasminogen 
activators included the cell surface anchored u-PA described 
above, as well as two vatiants of t-PA that were resistant o 
inactivation by PAI-1. Wild type t-PA and anchored u-PA pro- 
vided the highest levels of cell surface plasminogen activation. 
These two constructs were selected for use in in vivo experiments. 
In collaboration with Dr. Laurence Harker at Emory Univer- 
sity, we tested the ability of genetically engineered endothelial cells 
to decrease thrombosis n a baboon ex vivo shunt model. I2 In this 
experimental system, endothelial cells expressing t-PA or anchored 
u-PA were seeded at subcontinent density on short segments of 
collagen-coated, 4 mm diameter polytetrafluoroethylene graft ma- 
terial. The segments were placed in a femoral arteriovenous shunt, 
and blood was allowed to flow through the shunt at 40 ml/min 
for 60 minutes, or until the shunt clotted completely. The exposed 
collagen produces a thrombotic surface, on which platelets arid 
fibrin accumulate. The rate and amount of platelet and fibrin 
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accumulation were measured with radioactive tracers. Using this 
system, we found significant decreases in both platelet and fibrin 
accumulation on graft segments eeded with endothelial cells 
transduced with t-PA or anchored u-PA. Despite these significant 
antithrombotic effects along the graft surface, no evidence of 
systemic fibrinolysis was detected in peripheral blood. In addition, 
systemic t-PA and u-PA levels were unchanged before and after 
graft implantation i all animals. Thus the antithrombotic effects 
appeared exquisitely localized to the graft surface. This study 
proves the concept hat genetic modification of endothelial cells 
can enhance local fibtinolysis and suggests that this strategy might 
represent an effective approach to the prevention ofgraft hrombosis. 
While the results of the baboon study were promising, the 
clinical applicability of the baboon study was limited by two 
important considerations. First, the duration of the experiment 
was limited to 1 hour, due largely to animal care issues. An 
antithrombotic strategy that leads to a clinically significant in- 
crease in graft patency rates must produce effects that persist for 
years. Second, the blood flow rates in this study (40 ml/min) were 
below flow rates present in most human vascular prostheses. Low 
flow is necessary to provide a prothrombotic environment during 
the relatively short experimental period; however, seeded cell reten- 
tion must also be tested under the higher flow rates that are typically 
present in human vascular grafts. To begin to address these issues, we 
performed a series of studies in which seeded vascular grafts were 
implanted in the carotid and femoral arteries of sheep) 3 
We compared retention of endothelial cells transduced with 
the t-PA vector to retention of cells transduced with a control 
vector. Experiments were performed both in vitro (in a nonpulsa- 
tile flow system; 80 to 150 ml/min) and in vivo (150 to 240 
ml/min). Retention of t-PA-expressing cells on exposure to flow 
was significantly lower both in vitro and in vivo. In the in vivo 
experiments, virtually no t-PA-expressing cells remained on the 
grafts after 1 hour (median, 0% retention; range, 0% to 11%). In 
contrast, retention of the control-transduced cells was easily de- 
tected (median, 32%; range, 22% to 36%; p < 0.00001). We tested 
the hypothesis that the enhanced proteolytic activity of the t-PA- 
transduced cells was responsible for their decreased retention. In 
the in vitro flow system, addition of the protease inhibitor aproti- 
nin to the perfusion medium resulted in a signifcant increase in 
retention of the t-PA-transduced cells. These data suggest that the 
increased fibrinolytic activity detected in the low flow baboon 
system is also manifested as enhanced proteolysis in the ovine 
system, leading to cell detachment and loss from the graft surface 
on exposure to high flow rates. 
In summary, endothelial cells can be genetically modified to 
produce increased levels of fibrinolytic proteins. These proteins 
may be secreted or they may be dirccted to the apical cell surface, 
to enhance fibrinolysis pecifically along the vessel lumen. Fibrino- 
lyrically enhanced endothelial cells, when present on the surface of 
prosthetic graft material, can decrease thrombus dcposition in a 
nonhuman ptimatc model, under low flow conditions. However, 
enhancement of fibrinolysis may be accompanied by an increased 
susceptibility of transduced cells to detach from graft surfaces 
under high flow. Gene therapy strategies for decreasing raft 
thrombosis may require expression of antithrombotic molecules, 
such as hirudin, 14 that lack proteolyfic activity. In addition, these 
experiments demonstrate hat genetic interventions in complex, 
finely balanced biologic systems may have unanticipated out- 
comes. 
David A. Dichek, MD 
Gladstone Institute of Cardiovascular Disease 
University of California, San Francisco 
San Francisco, Calif. 
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CONTROL OF THROMBOSIS  AND INT IMAL  
THICKENING- - -ENDOTHEL IAL  SEEDING AND 
SODDING IN HUMAN BEINGS 
Cell transplantation a d tissue ngineering have been suggested as 
approaches to improve the function of implantable medical devic- 
es) ,2 These approaches involve methods whereby prosthetic ma- 
terials and biologically active cells are combined to form a compos- 
ite structure for implantation i to the body. The stimulus for 
creating these composite structures has been the failure of pros- 
thetic materials to function adequately astissue replacements. The 
replacement of arteries with purely prosthetic blood vessel grafts 
provides one example where prosthetic devices function poorly 
when surgically placed in small diameter or low flow locations like 
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the lower leg or coronary artery. Failure results due to thrombosis 
of  blood in the graft from both the thrombogenicity of the 
prosthetic lumenal blood flow surface as well as due to intimal 
thickening. Thus a successful prosthetic graft would be one that 
remained patent as a blood conduit, prevented thrombosis n low 
flow or adverse states, and controlled intimal thickening. Given 
that a prosthetic graft has not fulfilled these objectives, investiga- 
tors have examined whether the recreation of an endothelial cell 
lining would impart desirable qualities to the lumenal surface of a 
vascular graft that is not possible with a prosthetic graft. 2
A major effort toward improved synthetic graft function is the 
use of cell transplantation. As first developed and reported by Dr. 
Malcolm Herring in 1978, cell transplantation f vascular grafts is 
a method directed toward accelerating the formation of  an anti- 
thrombogenic cellular lining on the blood flow surface of  vascular 
grafts? The initial methods for this transplantation used venous 
segments as a source of  endothelium. Given the small number of 
cells available when autologous vein derived endothelium are used 
without culture, and concerns about culturing effects, investiga- 
tors have been pursuing alternate sources of endothelial cells for 
transplantation. Our group has reported methods for the isolation 
of autologous microvessel ndothelial cells from adipose tissue for 
use in cell transplantation. 4 The source of fat for this endothelial 
cell isolation was initially fat deposits associated with omentum. 
This fat is well vascularized, with a density of endothelial cells in 
excess of 106 endothelial cells per gram of fat isolated. The need 
to place cells in culture is obviated by the large number of endo- 
thelinm available per gram of  omental associated fat. However, 
access to omental associated fat still would necessitate a separate 
surgical procedure with related complications. 
Alternate anatomic sources for microvascularized autologous 
human fat for endothelial cell transplantation have been reported 
since these original reports. A significant improvement was the 
identification of subcutaneous fat as a source of  endothelial cells 
and the use of fiposuction to derive this fat from patients,  A 
patient undergoing endothelial cell transplantation therefore does 
not need to undergo a laparotomy to remove omental fat or 
undergo a separate vascular procedure to remove a segment of 
vein. Instead, asmall amount (50 ml) of  fat can be removed using 
a hand-held syringe cannula device. This procedure requires less 
then 5 minutes and requires a small skin incision or trocar punc- 
ture to insert he fiposuction cannula. 
The use of liposuction fat also is advantageous because the 
tissue is effectively minced during the liposuction removal process. 
Microscopic evaluation of  liposuction fat illustrates the morpho- 
logic characteristics of this tissue. The predominant cell type 
present is adipocytes. Recently, a complete characterization f
cells present in liposuction fat was reported and established that 
the major cell type present in this tissue was endothelinm. 6 
The methods for the isolation of endothelial cells from fat are 
essentially modifications of the methods reported by Wagner in 
1972 for the isolation of endothelial cells from rat epididymal fat 
pads. 7Human fat microvessel ndothelial cells are isolated by first 
digesting the fat with a proteolytlc enzyme mixture composed 
predominantly of collagenase and trypsin. The characteristics of
this enzyme are critical for successful isolation of endothelial cells 
from fat. 9 After collagenase digestion, the slurry is centrifuged 
resulting in the separation of buoyant adipocytes from more dense 
endothelium. The endothelial cell rich pellet is then used for cell 
transplantation procedures. 
The availability of  methods for endothelial cell isolation and 
culture as well as methods to deposit cells onto graft surfaces has 
resulted in numerous investigations to evaluate the efficacy of 
endothelial cell transplantation. 2,8 The earliest animal models were 
developed to evaluate the ability to accelerate the formation of 
endothelial cell linings on polymeric grafts. Most of these studies 
have been performed in the canine model due primarily to the 
acceptance of this animal model as a predictor of graft function in 
humans. Earliest studies established the ability to accelerate the 
formation of  a continuous monolayer of endothelial cells on the 
lumenal surface of vascular grafts. In general, monolayer forma- 
tion is highly dependent on the density of cells used to treat the 
graft surface. When cells are transplanted atconfluent densities or 
greater, monolayer formation appears to be complete in under 
three weeks. Subconfluent densities require more extended peri- 
ods of time. 
Subsequent studies using animal models have focussed on 
establishing the effects of endothelial cell transplantation f  graft 
patency. Complete review of the literature concerning endotheIial 
cell transplantation a d graft patency in animal models identifies a
large variation in the types and sizes (both i.d. and length) of graft 
materials tested, graft placement sites, anticoagulation used, types 
of animals (dog, pig, rabbit, rat, baboon), mad the type of  endo- 
thelial cells transplanted. Although there is very little consistency 
between author's methods, when graft patency is evaluated using 
more stringent statistical analysis a consistent positive benefit of  
endothelial cell transplantation on graft patency has been ob- 
served. Work in our laboratory has focussed on use of tissue 
engineered grafts for use as peripheral grafts, AV access grafts and 
coronary artery bypass grafts. Significant differences exist in the 
lumenal diameter and flow rates observed in these different ana- 
tomic positions, but a common result has been the ability to acceler- 
ate the formation of endothelial cell linings on these grafts. These 
results have prompted a number of researchers, including our group, 
to evaluate ndothelial cell transplantation in human trials. 
Our preclinical in vitro and in vivo studies have resulted in the 
establishment of an operating room compatible method for endo- 
thelial cell transplantation)° These methods have now been used 
in human clinical studies with patients requiring arterial and ve- 
nous bypass grafts and arteriovenous shunt grafts. Results of these 
human studies have now established the ability to form confluent 
endothelial cell linings on polymeric grafts in humans. Immuno- 
cytochemical studies of explanted graft segments have now estab- 
fished that the new endothelial cell lining exhibits characteristics of 
endothelial cells on native arteries. Surveillance of endothelialized 
grafts continues with patency evaluations in excess of 2 years. 
While the original goal of  endothelial cell transplantation 
studies has focussed on small diameter vascular grafts, the avail- 
ability of operating room-compatible methods for endothelial cell 
transplantation has expanded the possible application of these 
cells. The development of gene therapy methods has begun to 
target the endothelial cell as a vehicle for genetic manipulation. 
Endothelial cells reside at the interface between blood and tissue 
and therefore maintain astrategic position for the production and 
release of therapeutic materials. Molecular biologists have begun 
to take advantage of the extensive methodology established for 
endothelial cell transplantation. Reports of genetic modification of 
endothelial cells have exploded recently as the attractiveness of this 
cell is realized. The use of genetically modified endothelial cells 
has moved beyond prosthetic devices and studies are ongoing to 
establish the use of these cells in a variety of anatomic sites. Again, 
the availability of methods to easily isolate and transplant endothe- 
lial cells, especially subcutaneous fat derived microvessel ndothe- 
lial cells, provides an exciting new use for endothelial cell trans- 
plantation. 
Stuart K. Williams, PhD 
University of Arizona 
Tucson, Ariz. 
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LONG-TERM EFFECTS OF CL IN ICAL  IN V ITRO 
ENDOTHEL IAL IZAT ION ON GRAFTS 
Almost 20 years after the first reports on endothelial cell seeding, 
graft endothelialization through cell transplantation is still seen as 
an obscurity rather than a therapy. Given the history of clinical 
endothelial cell seeding, this sentiment is understandable. The 
determination f surgeons to avoid procedural complexity led to 
the premature clinical application of half-hearted techniques. The 
disappointing outcome of pilot studies meant an early death-kiss 
for an idea that had initially created alot of enthusiasm. Asa result, 
the majority of the pioneering roups pulled out, and the oppor- 
tunity to entrench the benefits of an endothelium on prosthetic 
graft surfaces was missed. Today, in view of the fascinating tools 
modern vascular biology is able to offer, this would certainly have 
helped to mobilize a much broader support for the tissue engi- 
neering efforts of the 1990s toward a spontaneously healing vas- 
cular prosthesis. 
As one of the few groups that did not abandon the idea of 
surface ndothelialization f vascular grafts in the mid-1980s, we 
decided to rectify procedural weaknesses before declaring endo- 
thelial cell transplantation inefficient. Because alow cell inoculum 
and an immature cytoskeleton seemed to be the main culprits for 
the failure of single-staged venous eeding, we elected to defy the 
surgical aversion towards cell culture procedures by confluently in 
vitro endothelializing prosthetic grafts. In a step-by-step a proach 
we developed reliable mass culture techniques for autologous 
endothelial cells 1 as well as precoating 2 and lining techniques 
which resulted in shear stress resistance of the endothelium. 3 After 
the preclinical proof of this concept in a nonhuman primate model 
was obtained, 4 we performed a randomized clinical study involv- 
ing 49 patients between 1989 and 1991. Based on the encourag- 
ing 3-year esults s and on the histologic proof of an endothelium 
on a 5-week explant 6 and a central graft segment after 41 months 
of implantation, 7 we commenced a clinical program of routine 
implantation of in vitro endothelialized grafts. We report here on 
the 7-year follow-up of the initial clinical study as well as the 3-year 
results of routine clinical endothelialization. 
Pat ients  and  methods  
Randomised trial (Phase 1). Between June 1989 and Decem- 
ber 1991, 49 patients (29 male and 20 female; mean age, 65.0 + 
9.8 years) entered this initial study. Details of this study were 
previously reported. 5 In brief, assignment to the endothelialized 
group (33 patients) and the control group (16 patients) followed a 
1:2 ratio. The selection criterion was the unavailability ofa suitable 
saphenous vein graft. Indications for surgery were disabling clan- 
dication in 37 patients (grade I chronic limb ischemia) and chronic 
limb ischemia in 12 patients (grade II in 6 patients and grade III in 
6 patients). In patients assigned to the endothelialized group, the 
right external jugular vein was excised with the patient under local 
anaesthesia, using a no-touch dissection and in situ cannulation. 1 
Endothelial cells were cultured in medium containing 20% autol- 
ogous serum. The mass culture of first passage ndothelial cells in 
two 165 cm 2 culture flasks was continued until the required cell 
number of 16 × 106 endothelial cells was confirmed by in situ 
counting? After reinforced 6 mm ePTFE grafts (W.L. Gore, 
Flagstaff, Ariz.) were precoated with clinically approved, fibrino- 
lyrically inhibited fibrin glue (Immuno, Vienna, Austria) they were 
incubated with human fibronectin (28 ~g/ml). Seeding of endo- 
thelial cells onto the graft surface (8.1 _+4.2 × l0 s EC/ml cell 
suspension) was performed in an automated, temperature- and 
pH-controlled rotation device (Microplan, Vienna, Austria). Sub- 
sequently, grafts were incubated for another 11.6 _+ 3.0 days to 
allow the maturation of the cytoskeleton, s Immediately after the 
seeding procedure and shortly before implantation, graft speci- 
mens were taken for scanning electron microscopy (SEM) and 
light microscopy. During implanation, grafts were not clamped 
and the culture medium was kept inside the prosthesis by gravity 
adjustment of the operating table. After nine patients were ex- 
cluded from the study due to growth failure of the autologous 
endothelial cells, 24 patients received 27 successfully endothelial- 
ized grafts (three underwent a bilateral procedure) and 16 patients 
received aunilateral untreated control prosthesis. In both groups 
three grafts were implanted below the knee. Follow-up studies 
were performed after 9 days, 3 months, 6 months, i year, and on 
an annual basis thereafter. Patency was determined by the ankle- 
brachial index (ABI) and duplex sonography at each time interval. 
Angiography was performed annually and in patients with sus- 
pected graft occlusion. Graft occlusion was suspected if a deterio- 
ration of the clinical status of the limb was confirmed by a signifi- 
cant drop in the ABI or a lack of flow signal on duplex sonography. 
Only primary graft patency was considered. During the entire 
observation period none of the patients were lost to follow-up. 
One patient in the control group and five patients in the endothe- 
lialized group died during follow-up for reasons other than pe- 
ripheral vascular problems. 
Routine clinical application (Phase 2): From June 1993 on- 
wards, in vitro endothelialization was offered to all patients under- 
going bypass operations for peripheral arterial occlusion. The 
selection criterion was again the lack of a suitable saphenous vein. 
Seventy-one patients received 80 successfully endothelialized 
ePTFE grafts (44 male and 27 female; mean age, 64.6 +- 9.7 
years). In nine patients an endothelialized prosthesis was bilater- 
ally implanted. Seventy-one graft implantations were done for 
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clinical grade I ischemia (56 above-knee, 15 below-knee), six for 
grade II (4 above knee, 2 below knee) and three for grade III (2 
above knee, 1 below knee). For routine clinical implantation only 
minor changes were made to the original procedures used in the 
randomized study. A new rotation device (Biegler Electronics, 
Vienna, Austria) was introduced that allowed quicker and easier 
handling of grafts during the lining process. Instead of 6-well 
plates, T 12 filter-protected culture flasks (Falcon, USA) were 
used for primary cultures. Instead of the external jugular vein, the 
cephalic vein was used as cell source. Due to the unavailability of
human fibronectin for clinical use, neither culture vessels nor 
grafts could be preincubated with it. ~ ~ qndium-labeling of plate- 
lets was also not performed in any of the patients of this second 
group. The time frame for the postoperative follow-up hardly 
differed from that of the randomised study: ABIs and duplex 
sonography were performed at 1 month, 3 months, 6 months, 1 
year, and from then onwards on an annual basis or at any deterio- 
ration of the clinical status. Angiography was only performed after 
1 year and on suspicion of graft occlusion. During the 34-month 
observation period, nine patients died of reasons other than pe- 
ripheral vascular disease. Hence again, no patient was lost to 
follow-up. Statistical analysis of the 78-month follow-up of our 
randomized trial (mean observation period, 60 months) and the 
34-month follow-up of the subsequent routine clinical implanta- 
tion of endothelialized grafts (mean observation period, 12 
months) was performed with STATISTICA (StatSoft, USA) soft- 
ware using the Kaplan-Meirer survivorship function for survival 
analysis and the log-rank test and Gehan's Wilcoxon group com- 
parison. 
Results and discussion 
In our phase 1 randomised trial, the Kaplan-Meier survivor- 
ship analysis showed a primary 3-year patency rate of 84.7% for 
endothelialized grafts and 55.4% for control grafts, s After 5 years 
it was 73.8% for the endothelialized group and 31.3% for the 
controls. At the end of the follow-up period, which lasted 6.5 
years, the primary patency rate for endothelialized grafts remained 
high at 73.8%, whereas that for control grafts dropped to zero. 
Performance differences between the two groups were statistically 
significant (log-rank test, p = 0.00098; Wilcoxon test, p = 
0.0025). 
The subsequent phase 2 routine clinical implantation ofendo- 
thelialized ePTFE grafts showed a 3-year primary patency rate of 
72.9% for all femoropopliteal reconstructions. 
The primary patency rate of both phases of our clinical in vitro 
lining program--which currently includes 107 endothelialized 
ePTFE grafts--was not only distinctly higher than that one of our 
own control group but also of comparable standard ePTFE grafts 
in previous mulicenter trials. 9,~° Veith et al. 9 reported a 3-year 
primary patency rate of 55% for all femoropopliteal reconstruc- 
tions with ePTFE grafts and a 5-year patency rate of 38%. 9 For 
above-knee ePTFE grafts, Prendiville t al?0 similarly recounted a 
3-year primary patency rate of 55% and a 5-year ate of 42%. Apart 
from this evidence for the superiority ofendothelialized grafts over 
untreated ePTFE prostheses, our primary patency rates of 84.7% 
and 72.9% at 3 years and 73.8% at 5 years even suggests that in 
vitro endothelialization makes prosthetic grafts an equal choice to 
saphenous vein grafts. In Veith's multicenter study 9 the patency 
rate for all reversed saphenous veins was 75% at 3 years and 68% at 
5 years. Taylor et al. equally reported primary patency rates of 78% 
at 3 years and 75% at 5 years for all reversed saphenous vein grafts 
in femoropopliteal position. Furthermore, ven the trend towards 
higher patency rates in below-knee positions--which Veith et al. 
describe for saphenous vein grafts--coincides with our findings in 
endothelialized prostheses. In phase 2 of our endothelialization 
program, the 62 grafts implanted in the above-knee position had a 
3-year patency rate of 71.0%, which compares well with Veith's 
70% for above-knee saphenous vein grafts. The 3-year primary 
patency rate for our 18 endothelialized below-knee grafts was 
81.9% compared to 80% that Veith et al. reported for similar vein 
grafts. 9
However, although the patency rate for in vitro lined ePTFE 
grafts was comparable with that one of vein grafts during both 
phases of our clinical endothelialization program, the primary 
patency rate of phase 2 was lower than phase 1. This difference 
may have several reasons. First, phase i - -as an initial randomized 
trial--included less patients that phase 2. Second, the follow-up 
time of phase 2 was shorter and implantations were conducted as 
clinical routine procedures, including substantially more redo op- 
erations than phase 1. Third, grafts had not been precoated with 
flbronectin, a potent adhesion molecule, due to the unavailability 
of a clinically approved product. 
In summary, 7 years of clinical in vitro endothelialization were 
able to prove two hypotheses: autologous endothelial cell lining 
significantly improves the patency of prosthetic small diameter 
vascular grafts, and a cell-culture dependent procedure can be 
easily carried over into clinical routine. 
Peter Zilla, MD, PhD 
University of Cape Town Medical School 
Cape Town, South Africa 
Mantled Deutsch, MD 
Johann Meinhart, PhD 
Vienna, Austria 
Teddy Fischlein, MD 
Munich, Germany 
Georg Hofmann, MD 
Wels, Austria 
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A B 
Fig. 1. Computed flow results for pulsatile flow in a carotid bifurcation. A, Computer  model. 
B, Isosurfaces of  velocity magnitude at peak systole demonstrate flow separation in carotid 
sinus. 
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MODEL ING OF BLOOD VESSELS 
Hemodynamic conditions, including velocity, shear, and pressure, 
play an important role in the modulation of vascular adaptation 
and the localization of vascular disease. 1,2,8-a° Consequently, un- 
derstanding the local hemodynamic environment in a region of 
the vascular system is an important field of research. As we enter 
the information age, the use of computer models to understand 
vascular blood flow, vessel deformation, mass transport, and vas- 
cular remodeling is emerging as a powerful theoretical tool to test 
hypotheses.S 7 As the models of vascular anatomy and physiology 
increase in complexity, the importance of having a comprehensive 
framework for computational vascular esearch will be of even 
greater import. The need for a comprehensive framework for 
computational vascular research motivated the construction f a 
Virtual Vascular Laboratory. The construction of computer mod- 
els of idealized and patient-specific models of vascular anatomy 
and physiology can now be performed quicldy enough to test 
hypotheses relating to vascular disease and adaptation i numero. 
In addition, these advanced computational methods have the 
potential to enable clinicians to predict he outcome of interven- 
tions to restore blood flow, a priori. 
The present work describes the results of computational mod- 
eling techniques to investigate hemodynamic conditions in the 
carotid bifurcation, and end-to-side anastomosis, an idealized 
model of an aorta, and a patient-specific model of an aorta con- 
structed from spiral CT data. 
A problem of considerable clinical importance is the pulsatile 
flow in a carotid artery. Plaques localize in the carotid sinus region 
where wall shear stress is low and particle residence time is high. 8 A 
computer simulation of the pulsatile flow in a carotid bifurcation 
was performed to quantify the hemodynamic conditions in the 
carotid bifurcation. The model geometry is shown in Fig. 1, A. 
Pulsatile flow conditions were used to compute the blood flow 
velocity patterns throughout the cardiac cycle. Fig. 1, B depicts 
isosurfaces of velocity magnitude at peak-systole, ranging from 0 
cm/sec along the wall to 20 cm/sec in the central flow stream. 
Half of the model is removed for visualization purposes. Note that 
in the carotid sinus region there is a large separation between the 
zero velocity isosurface representing the wall and the next surface, 
representing 5 cm/sec. This gap corresponds to a low velocity 
region and is observed at ll times during the cardiac ycle, con- 
firming in vitro observations of a region of flow stasis occurring 
along the outer wall of the carotid. Future investigations will 
incorporate compliant walls as well as oxygen and carbon dioxide 
transport to examine hypotheses of disease localization in the 
carotid sinus. 
Hemodynamic conditions, including low shear stress, are hy- 
pothesized to be one of the factors in the localization of the 
intimal thickening observed at the toe and floor of end-to-side 
anastomoses) A computer simulation of pulsatile blood flow in a 
model of a distal bypass anastomosis was performed and compared 
with in vitro experimental data? The contours of blood velocity 
and a comparison with experimental data are shown in Fig. 2. 
Excellent correlation between predicted velocity profiles and ex- 
perimental data was observed, validating the use of in numero 
methods for these problems. These simulations of blood flow in 
graft-artery anastomoses can provide a means to quantify the 
hemodynamic conditions for comparison with observed sites of 
intimal thickening. Further, once the mechanisms ofintimal thick- 
ening are better understood, computer modeling techniques can 
be used to design anastomoses that minimize adverse hemody- 
namic conditions. 
It is hypothesized that the beneficial effect of exercise in 
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Fig. 2. Pulsatile flow in an end-to-side anastomosis. A, Velocity contours and vector field at 
middiastole. B, Computed and experimental velocity component  in axial direction at a cross- 
section near the center of  the anastomotic region. 
A B 
Fig. 3. Pulsatile flow in the abdominal  aorta. A, Computer  model. B, Contours of  velocity 
magnitude and velocity vectors under resting conditions at middiastole. Note flow recirculation 
region in infrarenal aorta. 
retarding the progression of cardiovascular disease is due, at least 
in part, to the elimination of adverse hemodynamic conditions, 
including high particle residence time and low wall shear stress. In 
vitro and in vivo investigations have provided limited qualitative 
information on flow patterns in the abdominal orta and the effect 
of exercise on eliminating adverse hemodynamic conditions. 4 A 
computer model of a normal human abdominal aorta, shown in 
Fig. 3, A was created to simulate aortic blood flow under est and 
graded exercise, pulsatile, flow conditions, summarized in Table I. 
The pulsatile blood flow equations were solved, blood flow 
patterns noted, and shear stresses and particle residence times 
computed throughout the cardiac ycle. Fig. 3, B depicts contours 
of velocity magnitude and velocity vectors at middiastole under 
resting conditions. Mean shear stress at a point 2 em below the 
distal renal artery on the posterior wall, and particle residence 
time, defined by the time for 90% of instantaneously released 
particles to clear the infrarenal aorta, are presented in Table II. 
Moderate levels of exercise are su~icient to eliminate most of 
the adverse hemodynamic onditions in the infrarenal aorta 
present under resting conditions. Shear st ess increased by more 
than 400%, and particle residence time decreased by a factor of 3 in 
the infrarenal aorta• Complex, recirculating, flow patterns disap- 
peared. These data support he body of evidence that moderate 
levels of exercise have a beneficial effect on limiting atherosclerosis. 
The computer modeling techniques used in this investigation to
solve for the pulsatile flow in a normal aorta can also be applied to 
investigate hemodynamic conditions in cases involving aneurysmal 
and occlusive disease. These studies also provide impetus to exam- 
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Fig. 4. Three-dimensional reconstruction f  an abdominal aorta from spiral CT. A, Geometric 
model shows skin, blood flow domain, large clot, and calcifications. B, Axial velocity contours in 
the aneurysmal region. 
Tab le  I .  Tab le  I I .  
Resting Moderate Vigorous Resting Moderate Vigorous 
conditions exercise exercise conditions exerc ise  exercise 
Exercise level walking 4 to running 6 to Shear stress 0.5 2.3 4.7 
5 mph 8 rnph (dynes/era 2) 
Flow rate into 2.7 4.6 6.6 Particle residence 3.3 1.0 0.6 
abdominal orta time (see) 
(L/min) 
Heart rate (bpm) 67 100 133 
ine exercise hemodynamics n vivo using magnetic resonance im- 
aging techniques, and to assess the validity of common assump- 
tions made regarding the normal distribution of blood flow under 
varying physiologic conditions. 
The preceding examples demonstrate that computer models 
can be constructed and the blood flow characterized for idealized 
models representing the average anatomy of a group of individu- 
als. These idealized models can be modified ina systematic fashion 
to investigate he effect of variations in anatomy on flow condi- 
tions and are useful for quantifying hemodynamic factors in blood 
vessels prone to vascular disease. However, to determine the exact 
flow conditions in a given individual's vascular system for clinical 
diagnoses or surgical planning, models that more faithfully repre- 
sent individual anatomical features and flow conditions are neces- 
sary. These models can be constructed by extracting anatomic 
information from medical imaging sources including computed 
tomography (CT) and magnetic resonance imaging (MRI). Fig. 4, 
A displays a geometric model reconstructed from spiral CT data of 
a patient with an aneurysm in the abdominal aorta. The mural 
thrombus in the aneurysmal sac and calcifications along the vessel 
wall were identified in addition to the flow domain. The equations 
governing the pulsatile blood flow in this model were solved. Fig. 
4, B depicts a slice of the axial (primary) component of velocity 
along a plane through the aortic bifurcation. A slice plane was used 
to remove the top of the aneurysm for visualization of the flow. 
The top part of the model is then redisplayed in wireframe. Also 
shown is the large mural thrombus along the side wall of the 
aneurysm. As seen in Fig. 4, B, the flow decelerates a  it enters the 
aneurysmal cavity and a vortex develops in the anterior-posterior 
direction as noted by the negative flow (blue) along the back wall 
of the aorta and the positive flow (red) along the anterior wall just 
above the bifurcation. Reverse and stagnant flow is observed close 
to the wall of the aneurysm along the anterior and posterior wall of 
the aorta. These numerical investigations nto blood flow in an 
individual patient's vasculature can be used to augment the ana- 
tomical data provided by medical imaging diagnostics. Simula- 
tions of the stent-graft repair, including a femorofemoral bypass, 
were also performed. Presumably, with knowledge of the effect of 
hemodynamic conditions on vascular adaptation and disease, and 
the knowledge of the actual hemodynamic conditions in an indi- 
vidual patient, obtained using imaging and computer modeling 
techniques, better treatments can be devised to improve individual 
patient care. 
In conclusion, a novel approach to research into the relation- 
ship between hemodynamic factors and vascular adaptation and 
disease has been developed. Work to date has focused on the 
development of a theoretical nd computational framework for 
future research in the application of computational methods to 
vascular blood flow problems. Methods have been established 
which will permit he incorporation of mass transport and vessel 
deformability into the models, thereby enabling new investiga- 
tions into the mechanics of vascular disease and adaptation. Ulti- 
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mately, computational methods could serve as the basis for the 
development of quantitative, predictive tools to test hypotheses 
and address important clinical vascular problems. 
Christopher K. Zarins, MD 
Charles A. Taylor, PhD 
Thomas J. R. Hughes, PhD 
Stanford Medical School 
Stanford, Calif. 
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ENGINEERING THE CELLULAR-SYNTHETIC  
SUBSTRATE INTERFACE 
Biocompatibility, as it relates to interactions at the interface be- 
tween cells and a synthetic material, can be thought of as relating 
to information transfer, communication between a material and 
nearby cells in a biologic environment. Many of communication 
signals are biochemical innature, based on glycoprotein or glycos- 
aminoglycan structures that are either immobilized or diffusible. A 
precise knowledge of these biochemical communication signals 
can be exploited in the development ofmatetials that either mimic 
or block these signals. Examples in material design for vascular 
biocompatibility, wound healing, and tissue engineering will be 
addressed to illustrate the following basic operations in biomateri- 
als communication: (1) blocking untoward information provided 
by a tissue to cells in a healing response or by proteins adsorbed to 
a material to cells in an implant integration response; (2) providing 
new immobilized or diffusible information i  the aforementioned 
situations; and (3) providing in a material the ability to respond to 
a healing or implant integration environment, that is, building 
into a material the ability to listen, not just to speak, in a bidirec- 
tional communication. 
(1) The wound healing response of the body is somewhat 
over-designed for the modern medical context in which many 
"injuries" are performed intentionally in the form of surgery. In 
these cases, the rate of healing has little bearing on the surgical 
outcome, rather the correctness ofhealing is the ultimate interest. 
In these cases, we are thus interested in understanding and inter- 
feting with those signals displayed on an injured tissue surface that 
lead to the rapid formation of a scar tissueJ ,2 Polymers were 
designed to be placed conformally on the surface of the therapeu- 
tically injured artery before reexposure to blood flow; the purpose 
of this manipulation is to block the early deposition ofthrombus, 
which may be related to the later development ofintimal thicken- 
ing. The requirements of these polymers include ability to con- 
form to the arterial surface, remaining adherent under blood flow, 
and the ability to resist the attachment of blood platelets. Such 
material properties were obtained from multifunctional water- 
soluble prepolymers. These structures were copolymers of poly- 
ethylene glycol, flanked with small blocks of a degradable segment 
such as oligolactic acid, and terminated at both chain ends with a 
polymerizable group such as an acrylate. Interfacially photoihiti- 
ated polymerization of these precursors led to the formation on 
conformal tissue coatings, order 10 Ixm thick, that could extend 
over very long distances on the arterial surface. Control ofdegrad- 
ability of these materials could readily be achieved from i day to at 
least many months, thus providing the possibility of a tailored 
degradation response? Using this approach, it may be possible to 
obscure the information On the surface of an injured artery that 
communicates to the blood cells that the artery has indeed been 
injured. 
Manipulations as described above can readily be performed 
on the surfaces of material implants to obscure the information 
communicated byproteins that have adsorbed to the surface of the 
structural material. Activation of the material surface to achieve 
bonding of the structural phase with the more cell-passive over- 
coating phase is more difficult than on direct issue treatments, and 
the approaches used depend on the material under consideration. 
Photochemical detivatization f ePTFE has been explored, using 
photoinduced electron transfer reactions to defluotinate the 
ePTFE surface and thus provide sites for chemical derivatization 
with the overcoat material. 4 
(2) Having accomplished the obscuration of biologic recog- 
nition information as described in the preceding paragraphs, one 
would seek to display healing signals that would lead to the 
appropriate healing or implant integration outcome, for example, 
in this arterial environment reendothelialization without excessive 
intimal thickening. To begin to address this, adhesion peptides 
have been immobilized on biomatetial surfaces that are otherwise 
poorly adhesive, s,6 These peptides are targeted toward binding to 
adhesion receptors on cell surfaces, and in particular toward inte- 
grin receptors that are displayed on the surfaces of endothelial cells 
but not blood platelets. In this manner, itmight be feasible to take 
away the prothrombogenic character of the injured arterial surface 
and replace it with one that promotes reendothelialization. To 
achieve integrin interaction with immobilized peptides on highly 
swollen hydrogels, itWas necessary to link them into the hydrogel 
via a polyethylene glycol spacer approximately half the length of 
the polyethylene glycol diacrylate precursor from which the gel 
was formed. One might also consider the provision of diffusible 
information to the arterial intima from intraarterial or intragraft 
materials. 7 Approaches using materials with spatially controlled 
permeability o target delivery to the arterial media or graft Wall, 
JOURNAL OF VASCULAR SURGERY 
1116 Special Communication June 1997 
but not the blood in the lumen of the artery, depend on sequential 
polymerization of polymeric precursors with different molecular 
weights to thereby achieve different crosslink densities in different 
parts of the hydrogel material. 
(3) The approaches in the two preceding sections relate to the 
biomaterial either blocldng information (the first section) or send- 
ing information (the second). One would also like a biomaterial to 
be able to receive information from cells and tissues in a healing or 
implant integration response. To begin to address this, we have 
sought o understand the ways in which proteinaceous biomateri- 
als are remodeled by cells in healing responses, and to mimic this 
behavior in synthetic biomaterials. This was accomplished by de- 
signing materials with protease (collagenase, plasmin)-sensitive 
sites in the backbone, such that proteolytic attack led to the 
bioerosion of a cross-linked hydrogel. Collagenase and plasmin 
sensitive oligopeptides were grafted to flank polyethylene glycol, 
and the free termini of the peptides were acrylated, permitting the 
formation of a cro°slinked hydrogel as described above. These 
materials displayed egradation only in the presence of the appro- 
priate protease in vitro. Using this approach, it may be possible to 
permit he healing response to remodel amaterial and thus allow a 
true, two-way communication between material and body in a 
wound healing, medical implant, or tissue engineering environ- 
ment. 
Jeffrey A. Hubbell, PhD 
California Institute of Technology 
Pasadena, Calif. 
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THE IDEAL ENDOVASCULAR GRAFT 
The use of endovascular bypass techniques combining PTFE ma- 
terial and metallic stents is rapidly increasing.l-9 These techniques 
are used for nonocclusive vascular disease such as aneurysms, 
pseudoaneurysms, and arteriovenous and biliovenous fistulas, as 
well as for occlusive vascular disease. PTFE is preferred for small 
and medium-size vessels because of the relatively smaller profile of 
the stent-graft prior to deployment as compared with Dacron. 
Also, because PTFE is balloon-dilatable, it is suitable for simulta- 
neous placement of balloon- expandable stents. 10 
In general, stents and PTFE can be disposed relative to each 
other in three different arrangements: (1)stent attached at the end 
of freestanding PTFE conduit; (2) stent covered with PTFE on 
the outer surface; (3) stent covered with PTFE on the inner 
surface. An additional configuration is the PTFE-encapsulated 
stent, where the material covers both the inner and outer surface 
of the stent. The first three configurations can be fashioned with 
available materials and techniques. Embedded stents are experi- 
mental and not readily available. However, the mechanisms of 
healing of the first three configurations are fairly well understood 
from the available experimental nd clinical work. This evidence 
provides the fundamental observations from which to draw some 
practical conclusions. Freestanding PTFE-stent conduits do not 
form neointimal tissue except at the site where it overlaps with the 
stent. The thickness of such neointima ppears maller where the 
stent and PTFE overlap as compared with the portion of the stent 
in direct apposition to the arterial wall. n Stents covered by PTFE 
on the outer surface form an incomplete neointima that seems to 
form preferentially over the stent struts as compared with the 
PTFE surface) 2 When PTFE covers the stents on its inner surface 
the patency rate is lower and the intimal thickness greater, is
Similar esults were obtained with PTFE-encapsulated stents. The 
neointimal coverage was sparse and did not increase with time. 
Incomplete tissue cover resulted in layered thrombus formation 
and even in loss ofpatency. 
From these observations, it appears that the presence of a 
metal mesh inside PTFE vascular conduits may have favorable 
effects. This may be explained by the relative physicochemical 
characteristics of metals and polymers in regard to interactions 
with blood proteins and cells. 
Julio Palmaz, MD 
University of Texas Health Science Center 
San Antonio, Tex. 
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